

1. Company details

Name of entity:	Singular Health Group Limited
ABN:	58 639 242 765
Reporting period:	For the year ended 30 June 2024
Previous period:	For the year ended 30 June 2023

2. Results for announcement to the market

	30 June 2024 \$	30 June 2023 \$	Change \$	Change %
Revenues from ordinary activities	1,364,975	616,142	748,833	122%
Singular Health Group Limited	(4,924,704)	(5,390,318)	465,614	(9%)
Cost for the year attributable to the owners of Singular Health Group Limited	(4,924,704)	(5,390,318)	465,614	(9%)
Spividends here were no dividends paid, recommended or declared during the current financial period.				
The loss for the Group after providing for income tax amounted to \$4,	924,704 (30 June	2023: \$5,390,318	3).	
S. Net tangible assets				

Oers 0ers	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	0.68	(0.73)
0		

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.



7. Details of associates and joint operations entities

	Reporting entity's percentage holding		Contribution to profit/(loss)	
Name of associate/Joint operations entities	Reporting period %	Previous period %	Reporting period \$	Previous period \$
Australian Additive Engineering Pty Ltd ¹	-	25.00%	-	(126,196)
GeoVR Pty Ltd ²	-	50.00%	-	-
Singular International Medical Technology Ltd	50.00%	50.00%	-	-
Group's aggregate share of associates and joint venture entities' profit/(loss) (where material)				
Profit/(loss) from ordinary activities before income tax			-	(126,196)
Cincome tax on operating activities			-	-

Uuring the financial year, the Company dispose of its 25% shareholding in Melbourne-based Australian Additive Engineering Pty Ltd in Consideration of AUD\$70,000.

During the year, the Company divested the 50% interest in GeoVR Pty Ltd. The loan of \$2,200 provided was fully written off.

8. Audit qualification or review

The financial statements have been audited and an unmodified opinion has been issued.

9. Attachments

igodownhe Annual Report of Singular Health Group Limited for the year ended 30 June 2024 is attached.

10. Signed

Signed

Date: 29 August 2024

Denning Chong Managing Director



Singular Health Group Limited and its controlled entities

ABN 58 639 242 765

Annual Report - 30 June 2024

Singular Health Group Limited and its controlled entities Contents 30 June 2024



Corporate directory	2
Review of operations	3
Review of operations Directors' report	8
Auditor's independence declaration	25
Consolidated statement of profit or loss and other comprehensive income	
Consolidated statement of financial position	28
Consolidated statement of changes in equity	29
Consolidated statement of cash flows	
Notes to the consolidated financial statements	
Consolidated entity disclosure statement	73
Directors' declaration	74
Independent auditor's report to the members of Singular Health Group Limited	75
Corporate governance statement	79
ASX Additional Information	80

General information

The financial statements cover Singular Health Group Limited as a Group consisting of Singular Health Group Limited and the entities it Controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is Singular Health Group imited's functional and presentation currency.

Qingular Health Group Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office And principal place of business are:

Registered office

Principal place of business

Wevel 5/191 St Georges Terrace Perth WA 6000

2/41 Discovery Drive Bibra Lake WA 6163

description of the nature of the Group's operations and its principal activities are included in the Directors' report, which is not part of the financial statements.

Singular Health Group Limited and its controlled entities **Corporate directory** 30 June 2024



Directors	Denning Chong - Managing Director Howard Digby - Non-Executive Chairman Andrew Just - Non-Executive Director
Company secretary	Steven Wood
Registered office	Level 5/191 St Georges Terrace Perth WA 6000
Principal place of business	2/41 Discovery Drive Bibra Lake WA 6163
Share register	Automic Registry Services Level5, 191 St Georges Terrace Perth WA 6000 Telephone: +1300 288 664 (within Australia) +61 2 9698 5414 (outside Australia)
Auditor	Nexia Perth Audit Services Pty Ltd Level 3/88 William Street Perth WA 6000 Phone: (08) 6325 5462
Solicitors	Squire Patton Boggs Brookfield Place, Level 11/125 St Georges Terrace, Perth WA 6000 Phone: (08) 9429 7444
Bankers	National Australia Bank Level 14, 100 St Georges Terrace, Perth, WA 6000
Stock exchange listing	Singular Health Group Limited shares are listed on the Australian Securities Exchange (code: SHG)

(ASX



The Board is pleased to provide a review of the operations undertaken during the financial year by Singular Health Group Limited (**"Singular Health"** or **"the Company**") and its subsidiaries (**"the Group**").

During the year ended 30 June 2024 ("FY24"), the Group reached the substantial regulatory milestones of ISO13485:2016 certification and FDA510(k) clearance, a key focus was on securing a foothold in the targeted United States healthcare market and consolidating the Company's position through strategic initiatives across the commercial, corporate, and technical areas of the business.

Commercialisation Activities

With the receipt of the US **FDA510(k)** and appointment of a US Agent, the Company actively engaged in FY24 in the development of a Global Sales Partner Program, led by Singular's Chief Commercial Officer, Martina Mariano PhD.

During the year, the Company executed the "Enterprise-First" strategy that leverages the in-country expertise and pre-existing relationships of master distributors, sales and technical partners to unlock larger multi-year contracts with healthcare organisations in the USA and globally.



Figure 1: Dr Martina Mariano (SHG) and Edwin Rivera (CG1)

Aligned with this enterprise-first approach, the Company commenced with the signing of Charlie Golf One Solutions ("CG1") as the US Master Distributor for the 3Dicom software suite on the 5th of July 2023 with James Hill, COO, and Martina Mariano, CCO, representing Singular Health during a two-week trip to Miami and Washington DC.

As a Service-Disabled Veteran-Owned Small Business (**SDVOSB**), CG1, led by veteran Edwin Rivera, has the ability to tender for sole-source contracts, benefit from set-aside provisions for SDVOSB's from federal contractors and sub-contractors, and has a strong reputation within the large Miami-Dade veteran community.

Whilst in the United States, the scale of the existing problem in the market particularly in the United States with medical file sharing was very apparent, and the potential applications of the 3Dicom software was readily identified by CG1 and many of the related parties that met with Martina and James.

The size of the addressable market, the technical roadmap of the software, the potential opportunities and level of engagement just in Florida, resulted in CG1 and related US-based investors to deepen their involvement with Singular Health during the year as further detailed in *Corporate Developments* below.

3Dicom R&D in Medical Education & Training

The culmination of the 3Dicom MD[®] and 3Dicom R&D software on desktop, combined with concerted, consistent outbound sales and marketing efforts and remote demonstrations saw an increased level of interest in the 3Dicom software outside of Company's core demographic of the USA and practitioner-patient communications.

Sales partners were appointed in Europe, South-East Asia, Africa, and the Middle East who identified 3Dicom R&D as holding strong growth prospects in the medical education market, particularly in countries with religious sensitivities that limit the use of human cadavers.

These left-field opportunities resulted in Singular Health receiving its inaugural enterprise purchase order from Majmaah University in Saudi Arabia through a sales partner in December 2023, and additional interest from teaching hospitals and universities in Australia, South-East Asia, and Europe.

It is expected, based on feedback, that additional segmentation and annotation tools, driven by artificial intelligence models, within the 3Dicom ecosystem will accelerate the uptake of the 3Dicom R&D software within the education sector in the future.

Initial United States Enterprise Contracts

During the year, the Company received two pivotal enterprise contracts through CG1 consisting of:



- The provision of 5,000 3Dicom Patient licenses to veterans in the Miami-Dade County as part of an initiative funded by local healthcare organisations, veteran support agencies, and not-for-profits, to enable veterans to easily digitise, store, and share their medical images and improve patient outcomes, and
- The deployment of 25 3Dicom R&D and 2,500 3Dicom Patient licenses over a 2-year period to Roseman University of Health Sciences in Las Vegas, Nevada for use by students and patients operating in, and being treated at, Roseman's medical school.

These initial contracts in the United States are pivotal for the Company and its Master Distributor, CG1, as the successful implementation of the contracts will be likely be seen as a proof of concept by larger organisations who are awaiting validation of the technology in the United States prior to committing to purchase orders of their own.

As these rollouts have progressed, and with the Group undertaking numerous technical initiatives to improve scalability and deployment, negotiations with large overarching entities such as managed service organisations (MSO) and healthcare plans have steadily progressed.

Through the connections of CG1, and Marin and Sons, a strategic investor in the Company (see below), many doors have been opened into hospitals, outpatient clinics and primary care providers in Florida, Nevada, Georgia, and Texas.

Furthermore, CG1 provided a crucial introduction to Magic Leap, the world's leading manufacturer of enterprise augmented reality (AR) eadsets. This resulted in the Group undertaking a technical collaboration with Magic Leap to evolve 3Dicom VR into 3Dicom XR, a software solution compatible with the Magic Leap 2 headset and compliant with the Open XR standards for use across many VR/AR devices.

Ver on the West Coast of the USA, the Group has continued to enjoy an ongoing relationship with Sony Electronics with representation at multiple tradeshows within the United States and also in India through Sony Electronics India. These activities have helped to elevate the profile of the Company and the 3Dicom product and increase the opportunities for potential pathways to extend the relationship with Sony Electronics, including integration with their recently released XR headset.

During the year, the Group appointed Knox Labs, a well renowned VR / AR distributor in California, to represent the Company on the US

Ginally, the Group has also been steadily progressing negotiations with various multinationals and listed companies to expand its footprint outside of the United States.

Retention of Regulatory Certifications

With audits by PharmOut and BSI, the Company was recertified with ISO13485:2016, Medical Device Single Audit Program (MDSAP), and has retained compliance with the various requirements for its **FDA510(k)** clearance in the United States of America for the 3Dicom MD^{*} software.

Corporate Developments

During the year, the Group focused on strategic corporate developments, weathering difficult macro-economic conditions and leveraging relationships with US-based entities to mitigate dilution for existing shareholders by prudently managing cashflow until such time that the Group's commercialisation activities supported a significant placement at a higher share price in February 2024.

In beginning of the year, the Group made full repayment of the AUD\$800,000 of convertible notes to avoid dilution via conversion by taking on a short-term AUD\$500,000 debt facility with Foxlaw Investments Pty Ltd. Shortly after rationalising the balance sheet, and only 6 weeks after meeting in person to sign the Master Distribution Agreement, CG1 Ventures LLC, a related party of CG1, committed to invest AUD\$850,000 at 5.5 cents per share (a 41% premium to the share price at the time).

There were key appointments of Marin & Sons, an influential and well-connected Miami-based public relations firm, as Singular's public relations and corporate advisor in the US, along with the appointment of Kyla Garic as the Singular's Chief Financial Officer.

Subsequent to the Company's first major enterprise contracts, including the Miami 3Dicom for Veterans initiative purchase of 5,000 3Dicom licenses, the Company was able to enlist the support of Shaw and Partners' Perth office along with Grange Capital to successfully raise a AUD\$4.05 million placement at 11 cents per share (a 9.5% discount to the 14-day VWAP at the time) in February 2024.

Rounding out the strong levels of investment, Craig Sellars, co-founder of cryptocurrency Tether, made an AUD AUD\$1M investment at 15 cents per share (15% premium).



Finally, a follow-on investment by Marin & Sons of AUD\$773,000 at 16 cents per share (39% premium to share price at the time) in May 2024 was approved at an EGM held in late June 2024 and will bolster the cash at bank once received subsequent to the financial year end.

The Group also welcomed Dr Samuel Straface and Mr Craig Sellars to its Advisory Board during the year where they've been instrumental in providing product feedback and strategic advice on the Group's US commercialisation strategy.

Technical Development

As aforementioned in *Commercialisation Activities*, the FY24 year commenced with James Hill, COO/CTO, and Dr Martina Mariano PhD, CCO, spending several weeks in the United States meeting with prospective clients from small clinics to hospitals and large integrated healthcare organisations. The technical developments throughout the year have been focused less on adding new functionality and upon improving scalability and usability to drive large-scale onboarding and usage with minimal support.

Following a comprehensive series of strategic planning sessions in September 2023 incorporating observations about the future direction of healthcare provision in the US from key opinion leaders in Florida, the Company completed the functional development of the 3Dicom Patient, MD[°] and R&D software on desktop devices for local usage.

Whilst the natural progress is for the desktop versions of the software to be ultimately superseded by the online versions developed later in the year, the functional completion of the desktop applications was a fundamental prerequisite to progress commercial opportunities within secure environments such as defence and in China where internet access is restricted.

The completion of Singular Health's Medical File Transfer Protocol (MFTP) system and the lodgement of a patent application to protect this integral IP that forms the backbone of the Company's ability to securely and rapidly anonymise, encrypt, compress, share, store, and trace medical imaging records globally within the 3Dicom eco-system.

MFTP has been designed and developed with open endpoints to allow for 3rd party integrations with Picture Archiving and Communication Systems (PACS), Fast Health Interoperability Reporting (FHIR), and services such as AWS Sagemaker for AI models.

The second half of FY24 also witnessed the release of v3.5.2 of 3Dicom MD[®], research and development bringing a swathe of usability opdates to the desktop software and the ability for healthcare practitioners to go beyond the sharing of medical images and share of dditional medical imaging records such as radiological reports and key images.

As aforementioned, the further development of 3Dicom software for desktop was necessary to meet the requirement of potential ustomers in China and in the defence sector for software capable of offline use. The release of 3Dicom v3.5.2 in early March 2024 marked the completion of the technical development for the desktop applications across the following tiers:

- 1. **Patient Tier**: This is designed for patients to visualise their own medical scans in 3D, helping them understand their anatomy and medical conditions better.
- 2. **Patient Tier**: This tier is aimed at medical professionals, such as doctors and radiologists. It includes advanced features for diagnostic purposes, allowing for detailed analysis and real-time collaboration on medical images.
- 3. **R&D Tier**: This tier is tailored for researchers and developers. It provides tools for more-in-depth analysis and development, including features for medical device design and integration with other research tools.



Figure 2: Fully Documented, Licensable Software Development Kit (SDK) for Enterprise Licensing to 3rd Parties

Immediately subsequent to the v3.5.2 release, the Company's technical development was shifted to the creation of a selfcontained Software Development Kit (SDK) that can be licensed to 3rd parties and provides cloud-based and mobile applications with the Company's core Volumetric Rendering Platform and functionality.

This SDK, currently at v1.2.1, has been well documented and made available online for ease of integration by 3rd parties and into the Company's own cloud-based zero-footprint viewer that was released in June 2024.

Coupled with a public Application Programming Interface (API), this new technical stack has enabled the Company to enter into

numerous discussions with AI model developers, medical imaging hardware companies, and academic institutions about licensing and embedding of the technology within their offerings.



Critically, the strong demand for the 3Dicom Patient tier from the United States with 7,500 licenses purchased during FY24, has led to Singular Health's technical team expediting the migration of the Patient tier to an online solution. Through the launch of an online, zerofootprint viewer and coupled with the ability to upload and store medical imaging via an updated online portal, the onboarding process has been greatly improved for patients and veterans as opposed to downloading and updating of desktop software.

This improved user experience, launched publicly in early June 2024, has helped to accelerate commercialisation efforts and has fully addressed concerns from sales partners about the level of support required in the deployment of enterprise-level contracts. The cloudbased approach has also facilitated faster development and deployment of AI-models, with the 1.1.0 version of the online viewer utilising ChatGPT to help users better understand annotations and anatomical structures in their imaging.





Figure 3: 3Dicom Patient Online Viewer enables cloud storage, peer-to-peer sharing, and includes manual annotations

Singular Health's involvement in the public health initiative for Bone & Joint Health with Edith Cowan University (ECU) and the Arthritis Cand Osteoporosis Foundation of Western Australia (AOWA) continued during the year.

Singular Health has contributed towards the project over the past 18 months since inception through the provision of 3D assets, facilitating the creation of animated videos relating to bone and joint health, and in participation in various events and consultation sessions.

This project is the last non-software related project being undertaken by the Company in the academic sector and is due to be completed in October 2024.



Singular 3DP

Throughout the year, trading conditions for Singular 3DP, the

Company's wholly owned subsidiary slowed in both the provision of services and the resale of industrial 3D printers. Pressure of higher interest rates, delays in the deployment of federal funding via the Modernising Manufacturing Fund, and logistical issues with local customers and overseas suppliers during the year progressively slowdown in the volume of deals in the 3D printer resale pipeline given the capital nature of such sales, and accordingly pressure on the cash flow for Singular 3DP.

At the end of FY24, the Group ceased 3D printing machinery resale operations resulting in the redundancy of two staff members. The Company is currently negotiating the sale of the outstanding industrial 3D printer to various 3rd parties to maximise the return of capital and has no other outstanding obligations or machines in hand.

On the service side, Singular 3DP benefitted in the second half of FY24 from the purchase of a number of small formats Fused Deposition Modelling (FDM) that have yielded better unit economics than the pre-existing machines. Notwithstanding, most of the service-based



3D design and printing work has originated from outside of the medical sector. Despite improving unit economics and relatively low operating expenses.

In order to focus on the Company's medical software development and commercialisation and given the rapid traction being achieved by the Company for its software applications, management is actively exploring opportunities for the sale of the Singular 3DP business during FY24 and remained in negotiations with several interested parties as at the date of this report.



The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group') consisting of Singular Health Group Limited (referred to hereafter as the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the year ended 30 June 2024.

1. Information on Directors

The following persons were Directors of Singular Health Group Limited during the whole of the financial year and up to the date of this report, unless otherwise stated:

Name: Title: Qualifications: Experience and expertise:

Other current directorships:

Cher current directorships (last 3 years):

Other current directorships: Former directorships (last 3 years): Interests in shares: Interests in options: Interests in rights:

Mr. Howard Digby

Chairman and Non-Executive Director BEng (Hons) Mr. Digby, began, bis, career, at IBM, at

Mr. Digby began his career at IBM and has spent 25 years managing technology related businesses across the Asia Pacific region, of which 12 years were spent in Hong Kong ending with The Economist Group as Regional Managing Director. Prior to this he held senior management roles at Adobe and Gartner where his clients included major semiconductor players inclusive of Samsung, Hynix and TSMC. Upon returning to Perth, Howard served as Executive Editor of WA Business News and now spends his time as a company director, advisor and investor, having played key roles in several M&A and reverse takeover transactions. Non-Executive Director: Elsight Limited (ASX: ELS) Non-Executive Director: 4DS Memory Limited (ASX: 4DS) Non-Executive Director: Spenda Limited (ASX: SPX) N/A N/A 680,609 ordinary fully paid shares 2,250,000 unlisted options

N/A

Mr. Denning Chong

Chief Executive Officer and Managing Director Member of the Risk & Audit Committee LLB. Dist., B. Com Denning Chong has been the principal of James Chong Lawyers since 2004 having significant experience in cross border transactions, and large commercial and corporate due diligence and acquisitions.

Denning is on the Board of Directors of Mutual Ltd, a fund management business with over AUD\$3b under management. Denning is also a director for the Australian subsidiaries of SGX listed Hiap Hoe Limited and a director of Aloft Hotel Perth.

Denning is one of the founders of Singular Health and was involved in the early-stage funding and governance of Singular Health since its incorporation.

N/A

N/A 9,308,575 ordinary fully paid shares 17,568,182 unlisted options 17,200,000 performance rights



Name: Title: Board Committees: Qualifications: Experience and expertise:	 Mr. Andrew Just Non-Executive Director Member of the Risk & Audit Committee Bec, Hec, MBA, GAICD Andrew Just was formerly the Regional Director Asia Pacific for Radiometer, a Danaher Company and is currently CEO of Aeris Environmental. He has 30 years' global experience in delivering growth and scale competencies with leading Fortune 500 companies, including GE Healthcare, Danaher, Stryker, and Cochlear. Andrew has held a variety of senior leadership roles across diverse business functions, with expertise in sales and marketing, performance management, commercial transactions, and operations in both turnaround and growth
Other current directorships: Former directorships (last 3 years): Special responsibilities: Interests in shares: Interests in options:	environments. N/A N/A N/A 336,364 ordinary fully paid shares 2,000,000 unlisted options

The relevant interest of each director in the shares, and rights or options over such instruments issued by the companies within the Froup and other related bodies corporate, as notified by the directors to the ASX in accordance with **S205G(1)** of the *Corporations Act* 2001, at the date of this report is disclosed at above.

Q. Company secretary

Steven Wood is a Principal at Automic Group, specialising in company secretarial and financial management services. Steven is a chartered Accountant and provides company secretarial and financial management services to both ASX and unlisted public and private companies. He has been involved in various private, seed capital raisings as well as successful ASX IPO listings, and has experience in takeovers and schemes. Prior to joining Automic, Steven was a Director at Grange Consulting Group Pty Ltd for 12 years.

Mr. Wood is currently Non-executive Director for Metalicity Limited (ASX: MCT) and Uvre Limited (ASX: UVA) and Company Secretary for number of ASX listed entities including Caspin Resources Limited (ASX: CPN) and Anax Metals Limited (ASX: ANX).

3. Meetings of Directors

The number of meetings of the Company's Board of Directors ('the Board') held during the year ended 30 June 2024, and the number of meetings attended by each Director were:

Director	Board Mee	etings
	Attended	Held
0		
Mr. Howard Digby	5	5
Mr. Denning Chong	5	5
Mr. Andrew Just	5	5

Held: represents the number of meetings held during the time the Director held office.

4. Principal activities

During the financial year the principal continuing activities of the Group consisted of:

- (1) Establishment of Enterprise Distribution Channels;
- (2) Sales and Marketing of 3Dicom;
- (3) Corporate Activities;
- (4) Quality and Regulatory;
- (5) Ongoing Product Development; and
- (6) Global3D Hardware Sales & 3D Printing Services.

During the year, the Group has discontinued its operation in Singular 3DP Pty Ltd, and the Company has classified the Singular 3DP business as held for sale in this financial report.



5. Material business risks

Protection and ownership of intellectual property rights

The Group seeks to protect its intellectual property through patents, trademarks, trade secrets, copyright and know-how. Whilst the Group protects its intellectual property through these measures, there can be no guarantee that there will not be any unauthorised use or misuse of its intellectual property or reverse engineering of its software by competitors.

If the Group fails to protect its intellectual property, competitors may gain access to proprietary information which could harm the Group's business.

There is a risk that the Group will not be able to register or otherwise protect new intellectual property it develops in the future. Competitors may be able to work around any of the applications or other intellectual property rights used by the Group, or independently develop technologies or competing products that are not covered by the Group's intellectual property rights. This may materially adversely impact the Group's revenue, legal expenses and profitability.

If the Group believes its intellectual property rights have been infringed, it may initiate or otherwise be involved in litigation against third parties for infringement, or to establish the validity, of the Group's rights. Any litigation, whether or not successful, could result in significant expense to the Group and divert the efforts of its personnel. In addition, any infringement could result in revenue loss and may be detrimental to Singular Health's reputation and brand value.

Singular Health's commercial success is, to a large extent, reliant upon its intellectual property being suitably protected and providing the Group with enforceable rights (through the registration of patents and trademarks). The Group cannot give assurance that the patents, trademarks or other intellectual property in existence today or created in the future will be able to be adequately protected.

Beliance on senior personnel

Singular Health's operational success will depend substantially on the continuing efforts of its key management personnel and on its ability to attract and retain key quality staff and consultants.

The Group relies on experienced managerial and highly qualified technical staff to develop and operate its technology and to direct reperational staff to manage the operational, sales, compliance and other functions of its business.

The loss of one or more of Singular Health's key management personnel could have an adverse impact on the Group's operations and financial performance. The Group's key personnel include its Managing Director, Chief Operating Officer, and Chief Commercial Officer. Ithough these individuals have entered into contracts with the Company, there is no assurance that such contracts will not be terminated. If such contracts are terminated or breached, or if these individuals no longer continue in their current roles, new personnel will need to be employed, which may adversely affect the business.

The Group is substantially dependent on the continued service of its existing development personnel due to the complexity of its products and technologies. There is no assurance that the Group will be able to retain the services of these people or that the Group will be able to recruit suitably qualified and talented staff in a time frame that meets the growth objectives of the Group.

Additional requirements for capital

As the Group's current business grows, and new lines of business are developed, the Group will require additional funding to support the ongoing development and commercialisation of its technology and to provide working capital. Although the Directors believe that the Group will have sufficient working capital and capacity to carry out its short-term business objectives, there can be no assurance that such objectives can be met without further financing or, if further financing is necessary, that financing can be obtained on favourable terms or at all. Further, if additional funds are raised by issuing shares, this may result in dilution for some or all of the shareholders. Any inability to obtain financing (if required) would have a material adverse effect on the group's business, financial condition and results of operations.



Certification of new applications / products and clinical trials

Singular Health has identified numerous certifications further to the FDA510(k) clearance issued in October 2022 that may allow for the use of 3Dicom in a diagnostic capacity including, TGA Class II, Health Canada clearance and CE Approval for the use of 3Dicom as a diagnostic SaMD.

Singular Health is also developing a number of new applications in the fields of additive manufacturing, anatomical education and artificial intelligence. These new products, as well as any future iterations of 3Dicom, may require continual clearances for new diagnostic and/or surgical planning tools and any new features may be required to undergo clinical studies and those studies may show that the new products or the new features (as the case may be) do not work in a safe and effective manner or that they do not meet the standards required for commercial release. If the new products or the new features do meet the required standards (and there is no guarantee that they will) then there is a risk that Singular Health will not be able to compete with other clinically approved technological developments in the market sectors in which it operates.

Singular Health may conduct clinical studies of new software it develops in the future, but there can be no guarantee that relevant regulatory agencies will allow Singular Health to undertake such trials and/or the development and approval process for any new products or applications of existing products may take longer, cost more than expected and may result in the new software not producing a viable device.

Pepending upon the severity of any failure of Singular Health to comply with any applicable regulations, Singular Health could be subject of enforcement actions, including but not limited to warning letters, fines, injunctions, consent decrees, civil monetary penalties, recalls resizures of its devices, manufacturing restrictions, closure of its manufacturing factories, modifications or revocations of any dearances and approvals that it already holds or will hold, and/or criminal prosecution. If any such sanctions are imposed against Singular ealth, such sanctions could harm Singular Health's reputation and, depending upon the severity, could have significant adverse impact n Singular Health's ability to provide services and on its financial performance and condition.

Competition

The industry in which Singular Health is involved is subject to increasing global competition which is fast-paced and fast-changing. The Company will have no influence or control over the activities of its competitors, whose activities or actions may negatively affect the operating and financial performance of the Group's business. For instance, competing companies may develop technology that upersedes Singular Health's technology.

The size and financial strength of some of the Group's competitors may make it difficult for Singular Health to maintain a competitive osition in the medical technology market. A number of third-party competitors are offering products and services similar to Singular ealth's products. Existing competitors and new competitors entering into the industry may develop superior technology offerings or have enhanced scale benefits, which may have a material adverse effect of the Group's revenue and financial performance.

Medical or product liability risk

Generally, medical technology companies may be subject to claims alleging negligence, product liability or breach of warranty that may involve large claims and significant defence costs whether or not such liability is imposed. These claims may be brought by individuals seeking relief for themselves, or increasingly, by Company's seeking to represent a class. Claims could be made against Singular Health for liabilities resulting from adverse medical consequences to patients.

Privacy risks

Singular Health collects, stores and processes highly sensitive, highly regulated and confidential medical imaging data. There is a risk that the measures the Group takes may not be sufficient to detect or prevent unauthorised access to, or disclosure of, information collected in relation to the Group's customers, end-user patients, employees and other sources of personal information. This may expose the Group to reputational damage, legal claims, termination of the Group's contracts, and regulatory scrutiny and fines, any of which could materially adversely impact the financial performance and prospectus of the Group.

The Group's security measures are subject to various risks including failure of end-users to comply with instructions for use, computer viruses, physical theft, physical damage resulting in a loss or corruption of data, operating system failures or similar disruptions. There is a risk that failure to adequately safeguard against any and all of these risks may result in a data breach, or a third party may gain access to confidential information of Singular Health's customers, end-user patients or employees.

In addition, any security or data issues experienced by other software companies globally could adversely impact client's trust in providing access to personal data generally, which could adversely affect the Group's ability to provide its service generally.



Technology changes

The Group participates in a competitive environment. Information technology systems are continuing to develop and are subject to rapid change, while business practices continue to evolve. The Group's success will in part depend on its ability to offer services and systems that remain current with the continuing changes in technology, evolving industry standards and changing consumer preferences. There is a risk that the Group will not be successful in addressing these developments in a timely manner, or that expenses will be greater than expected. In addition, there is a risk that new products or technologies (or alternative systems) developed by third parties will supersede the Group's technology. This may materially and adversely impact the Group's income and profitability.

Regulatory risks

The Group's operations may become subject to regulatory requirements, such as licensing and reporting obligations, which would increase the costs and resources associated with regulatory compliance. Any such increase in the costs and resources associated with regulatory compliance could impact upon the Group's income. In addition, if regulators took the view that the Group had failed to comply with regulatory requirements, this could lead to enforcement action resulting in public warnings, infringement notices or the imposition of a pecuniary penalty. This could lead to significant damage to the Group's reputation and consequently impact on its income.

The Group may offer its products, and any future developed products, throughout the world. Regulatory changes could see the Group being required to hold a license in some of these jurisdictions or otherwise comply with local regulations. This could preclude the Company from offering certain services in these jurisdictions until such a license has been obtained or may require the Group to comply with a range of regulatory requirements. Any such increase in the costs and resources associated with the regulatory compliance in these jurisdictions could impact upon the Group's income.

Q. Financial review

CAs disclosed in the financial report, the Group recorded an operating loss of \$4,924,704(30 June 2023: \$5,390,318) and a cash outflow from operating activities of \$2,440,289 for the year ended 30 June 2024 (30 June 2023: \$2,402,669). As at 30 June 2024, the Group had cash and cash equivalents of \$1,453,360 (30 June 2023: \$691,513) and had a positive working capital of \$1,289,767(30 June 2023: deficit \$1,720,860).

Significant changes in the state of affairs

Befer to review of operations for significant changes in the state of affairs during the year. The Company finalised an agreement to pispose of its 25% shareholding in Melbourne-based Australian Additive Engineering Pty Ltd in consideration of \$70,000. Additionally, it also divested the 50% shareholding in GeoVR Pty Ltd.

Guring the year, the Group has discontinued its operation in Singular 3DP Pty Ltd, and the Company has classified the Singular 3DP Obusiness as held for sale in this financial report.

There were no other significant changes in the state of affairs of the Group during the financial year.

Dividends

There were no dividends paid, recommended or declared during the current or previous financial year.



8. Matters subsequent to the end of the financial year

Date	Details
4 July 2024	The Company received the AUD\$1 million investment from Craig Sellars, as previously announced on 14 March 2024 and approved by shareholders on 27 June 2024. The Company issued 6,666,667 fully paid ordinary shares at 0.15 per share to Craig Sellars on 25 July 2024.
15 July 2024	The Company has received a binding purchase order for 5,000 additional 3Dicom patient annual licenses.
25 July 2024	 The Company has issued the following securities following the shareholders' approval on 27 June 2024: 336,364 fully paid ordinary shares to Director Andrew Just in lieu of cash payment of Director fees. 378,218 fully paid ordinary shares to Director Howard Digby in lieu of cash payment of Director fees. 1 million fully paid ordinary shares to Nigel Brown (subject to 24-month voluntary escrow) 2,775,000 fully paid ordinary shares to the Company's employees as a result of the conversion of vested performance rights, pursuant to the terms of the Company's Employee Incentive Plan. 8 million unlisted options exercisable at 0.15 and expiring 25 July 2027 to Shaw and Partners Limited (or their nominee/s). 10 million performance rights to Mr. Denning Chong, subject to vesting conditions.
	Refer to Notice of Meeting dated 21 May 2024 for further details in respect of the above allotments.
19 August 2024	The following Company securities lapsed and expired:
	- 800,000 options with an exercise price of \$0.24 expired on 19 August 2024.
D D	 - 500,000 options with an exercise price of \$0.30 expiring 30 November 2025 lapsed as conditions have not been satisfied. - 625,000 performance rights lapsed of conditional right to securities as conditions have not been satisfied.

No other matter or circumstance has arisen since 30 June 2024 that has significantly affected, or may significantly affect the Group's perations, the results of those operations, or the Group's state of affairs in future financial years.

9. Likely developments and expected results of operations

formation on likely developments in the operations of the Group and the expected results of operations have not been included in this operations because the Directors believe it would be likely to result in unreasonable prejudice to the Group.

0. Environmental regulation

The Group is not subject to any significant environmental regulation under Australian Commonwealth or State law.

11. Shares under option

Nissued ordinary shares of Singular Health Group Limited under option at the date of this report are as follows:

L		Exercise	Number
Date of options issued	Expiry date	price	under option
12-Feb-21	10-Feb-25	\$0.300	19,250,000
23-Nov-21	20-Dec-25	\$0.300	2,030,000
28-Nov-22	23-Dec-25	\$0.400	5,000,000
25-Jan-23	25-Jan-26	\$0.200	1,720,000
16-Jun-23	26-Jun-26	\$0.100	19,674,651
14-Aug-23	14-Aug-26	\$0.100	3,636,363
9-Feb-24	9-Feb-27	\$0.100	7,727,272
10-Nov-24	8-Dec-27	\$0.080	15,500,000
27-Jun-24	8-Dec-27	\$0.080	4,000,000
25-Jul-24	25-Jul-27	\$0.150	8,500,000
			87,038,286

No person entitled to exercise the options had or has any right by virtue of the option to participate in any share issue of the Company or of any other body corporate.



12. Shares issued on the exercise of options

The following ordinary shares of Singular Health Group Limited were issued during the year ended 30 June 2024 and up to the date of this report on the exercise of options granted:

Date options granted	Exercise price	Number of shares issued
21-Feb-24	\$0.100	766,267

13. Shares under performance rights

Unissued ordinary shares of Singular Health Group Limited under performance rights at the date of this report are as follows:

		Exercise	Number
Grant date	Expiry date	price	under rights
12-Feb-21	31-Dec-24	\$0.000	5,000,000
14-Dec-22	14-Dec-25	\$0.000	2,500,000
28-Nov-22	29-Nov-25	\$0.000	2,000,000
14-Dec-22	14-Dec-25	\$0.000	1,250,000
28-Nov-22	29-Nov-25	\$0.000	1,000,000
1 0-Nov-23	08-Dec-27	\$0.000	9,950,000
20-Sep-23	20-Sep-25	\$0.000	4,500,000
2 5-Jul-24	30-Jun-28	\$0.000	10,000,000
			36,200,000

No person entitled to exercise the performance rights had or has any right by virtue of the performance right to participate in any share issue of the Company or of any other body corporate.

4. Shares issued on the exercise of performance rights

the following ordinary shares of Singular Health Group Limited were issued during the year ended 30 June 2024 and up to the date of this report on the exercise of performance rights granted:

granted	Exercise price	Number of shares issued
Q _{1-Feb-24}	\$0.110	150,000
21-Feb-24	\$0.110	188,877
10-Nov-23	\$0.100	2,775,000
		3,113,877

15. Indemnity and insurance of officers and auditors

The Group has indemnified the Directors and executives of the Group for costs incurred, in their capacity as a Director or executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the Company paid a premium in respect of a contract to insure the Directors and executives of the Group against a liability to the extent permitted by the *Corporations Act 2001*. The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium.

The Group has not otherwise, during or since the end of the financial year, except to the extent permitted by law, indemnified or agreed to indemnify an officer or auditor of the company or of any related body corporate against a liability incurred as an officer or auditor.

16. Non-audit services

There were no non-audit services provided during the 30 June 2024 and 30 June 2023 by the auditor.



17. Proceedings on behalf of the Company

No person has applied to the Court under section 237 of the *Corporations Act 2001* for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

18. Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is set out immediately after this Directors' report.

19. Rounding off

The Group is of a kind referred to in ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191 and in accordance with that Instrument, amounts in the consolidated financial statements and directors' report have been rounded off to the dollars, unless otherwise stated.



20. Remuneration report (audited)

The remuneration report details the key management personnel remuneration arrangements for the Group, in accordance with the requirements of the Corporations Act 2001 and its Regulations.

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Group, directly or indirectly, including all Directors.

The remuneration report is set out under the following main headings:

- 20.1 Principles used to determine the nature and amount of remuneration
- 20.2 Details of remuneration
- 20.3 Service agreements
- 20.4 Share-based compensation
- 20.5 Additional information
- 20.6 Additional disclosures relating to key management personnel

20.1 Principles used to determine the nature and amount of remuneration

The objective of the Group's executive reward framework is to ensure reward for performance is competitive and appropriate for the results delivered. The framework aligns executive reward with the achievement of strategic objectives and the creation of value for shareholders, and it is considered to conform to the market best practice for the delivery of reward. The Board of Directors ('the Board') ensures that executive reward satisfies the following key criteria for good reward governance practices:

- Competitiveness and reasonableness,
- Acceptability to shareholders,
- Performance linkage / alignment of executive compensation, and
- Transparency.

The Nomination and Remuneration Committee is responsible for determining and reviewing remuneration arrangements for its Directors Gand executives. The performance of the Group depends on the quality of its Directors and executives. The remuneration philosophy is **C**to attract, motivate and retain high performance and high quality personnel.

Che reward framework is designed to align executive reward to shareholders' interests. The Board have considered that it should seek the reward tranework is designed to a solution of the enhance shareholders' interests by:
 having economic profit as a core of focusing on sustained growth in s increasing return on assets as well attracting and retaining high calib

- having economic profit as a core component of plan design,
- focusing on sustained growth in shareholder wealth, consisting of dividends and growth in share price, and delivering constant or
- increasing return on assets as well as focusing the executive on key non-financial drivers of value, and
- attracting and retaining high calibre executives.

Additionally, the reward framework should seek to enhance executives' interests by:

- rewarding capability and experience,
- reflecting competitive reward for contribution to growth in shareholder wealth, and
- providing a clear structure for earning rewards.

In accordance with best practice corporate governance, the structure of non-executive Director and executive Director remuneration is separate.

Non-executive Directors remuneration

The Constitution and ASX listing rules require the aggregate non-executive Directors' remuneration be determined periodically by a general meeting. The most recent determination was at the Annual General Meeting held on 28 November 2022, where the shareholders approved a maximum annual aggregate remuneration of \$500,000.

Executive remuneration

The Group aims to reward executives based on their position and responsibility, with a level and mix of remuneration which has both fixed and variable components.



The executive remuneration and reward framework has four components:

- base pay and non-monetary benefits
- short-term performance incentives
- share-based payments
- other remuneration such as superannuation and long service leave

The combination of these comprises the executive's total remuneration.

Directors' fees

The amount of remuneration the directors receive must not exceed fixed sum of \$500,000 per annum as approved at the General Meeting on 28 November 2022.

Remuneration of executives consists of an un-risked element (base pay) and performance-based bonuses based on performance in relation to key strategic, non-financial measures linked to drivers of performance in future reporting periods. No performance-based bonuses were paid during the year ended 30 June 2024.

Additional fees

A Director may also be paid fees or other amounts as the Directors determine if a Director performs special duties or otherwise performs services outside the scope of the ordinary duties of a Director.

A Director may also be reimbursed for out-of-pocket expenses incurred as a result of their directorship or any special duties.

Retirement allowances for directors

Superannuation contributions required under Australian superannuation guarantee legislation continue to be made and are deducted from the directors' overall fee entitlements where applicable.

Executive pay

In determining executive remuneration, the Board aims to ensure that remuneration practices are:

competitive and reasonable, enabling the company to attract and retain key talent;

aligned to the company's strategic and business objectives and the creation of shareholder value;

transparent; and

• acceptable to shareholders.

The executive remuneration framework has four components:

base pay and non-monetary benefits;

short-term performance incentives;

- other remuneration such as superannuation and long-service leave; and

- long-term incentives through participation in the Singular Employee Share Option Plan.

Base pay

Executives receive their base pay and benefits structured as a total employment cost (TEC) package which may be delivered as a combination of cash and prescribed non-financial benefits at the executives' discretion.

Executives are offered a competitive base pay that comprises the fixed component of pay and rewards. Independent remuneration consultants provide analysis and advice to ensure base pay is set to reflect the market for a comparable role.

Base pay for executives is reviewed annually to ensure the executive's pay is competitive with the market. An executive's pay is also reviewed on promotion.

There are no guaranteed base pay increases included in any executives' contracts.

There are no short-term incentives outstanding.

Benefits

No benefits other than noted above are paid to Directors or Management except as incurred in normal operations of the business.



Short term incentives

No benefits other than remuneration disclosed in the remuneration report are paid to Directors or Management except as incurred in normal operations of the business.

Long term incentives

During the year, the Company issued unlisted options and performance rights to the Directors and KMP. The details of the options issued are disclosed in 20.4 Share-based compensation of the remuneration report. The value of vested options granted in previous reporting periods was determined based on the intrinsic value of the options at the date of vesting, being the difference between the share price on that date and the exercise price payable by the KMP.

Remuneration consultants

The Company did not engage any remuneration consultants during the year.

The Company will engage independent remuneration consultants should it look to make any changes to director fee levels to ensure they are in line with market conditions and any decisions are made free from undue influence from members of the Company's KMP's.

Group performance and link to remuneration

Remuneration for certain individuals is directly linked to the performance of the Group. The relative proportions of remuneration that re linked to performance and those that are fixed are disclosed 20.2 Details of Remuneration of the remuneration report. The proportion of remuneration that is linked to performance relates to the vesting of performance rights issued to key management personnel, the terms of which are disclosed in 20.4 Share-based compensation of this report. The Directors assess performance of the 🕼 roup with regard to the achievement of both operational and financial targets with a focus on sales revenues and share price. Directors (And employees are issued performance rights to encourage the alignment of personal and shareholder interests.

Voting and comments made at the Company's 10 November 2023 Annual General Meeting ('AGM')

At the 10 November 2023 AGM, 98% of the votes received supported the adoption of the remuneration report for the year ended 30 (Dune 2023. The Company did not receive any specific feedback at the AGM regarding its remuneration practices.

0.2 Details of remuneration

Mounts of remuneration

🕼 etails of the nature and amount of each major element of remuneration of each Director of the Company, and other key management Howard Digby (Non-Executive Chairman)
 Denning Chong (Managing Director and Chief Executive Andrew Just (Non-Executive Director)
 James Hill (Chief Operating Officer)
 Martina Mariano (Chief Commercial Officer) from 9 Fee
 Kyla Garic (Chief Financial Officer) from 13 November

- Denning Chong (Managing Director and Chief Executive Officer)

- Martina Mariano (Chief Commercial Officer) from 9 February 2024
- Kyla Garic (Chief Financial Officer) from 13 November 2023
- Thomas Hanly (Managing Director and Chief Executive Officer) from 1 July 2022 to 14 April 2023
- Prof Kwang Guan Tay (Executive Director of Innovation and Research) from 1 July 2022 to 24 March 2023
- Denning Chong (Non-Executive Director) from 1 July 2022 to 14 April 2023

There were no service agreements or director fees arrangement with the subsidiary directors.



				Post-			
	Short-term benefits	Short-term benefits	Short-term benefits	employment benefits	Long-term benefits	Share-based payments	
	Cash salary and fees	Cash bonus	Annual leave	Super- annuation	Long service leave	Equity- settled	Total
30 June 2024	\$	\$	\$	\$	\$	\$	\$
Non-Executive Directors:							
Howard Digby ¹	50,000	-	-	5,500	-	30,753	86,25
Andrew Just ¹	40,000	-	-	4,400	-	24,602	69,00
Executive Directors:							
Denning Chong ²	(30,000)	100,000	23,682	27,399	-	444,534	565,61
Other Key Management Personnel:							
James Hill	139,259	-	15,676	14,478	-	155,324	324,737
Kyla Garic ³	-	-	-	-	-	-	
Martina Mariano	118,451	-	6,281	12,285	-	59,506	196,523
	317,710	100,000	45,639	64,062	-	714,719	1,242,130

During the period from March 2024 to 30 June 2024, fees were settled in cash. Fees were accrued for the period from July 2023 to February 2024 and are payable after the financial year in shares, as approved by the shareholders on 27 June 2024.

During the year, reimbursement from Mr. Chong related to surrender of salary for the period from 14 April 2023 to 30 June 2023.

Corporate Pty Ltd, of which Kyla Garic is a director, received provide financial services. This transaction was disclosed in **20.6**. COnyx Corporate Pty Ltd, of which Kyla Garic is a director, received \$65,000 excluding GST (30 June 2023: \$nil) during the year for

ers	Short-term benefits		Post- employment benefits	Long-term benefits	Share-based payments		
O 3 0 June 2023	Cash salary and fees \$	Cash bonus \$	Annual leave \$	Super- annuation \$	Long service leave \$	Equity- settled \$	Total \$
Non-Executive Directors:							
Howard Digby ¹	59,811	-	-	-	-	38,403	98,214
Andrew Just ²	41,246	-	-	3,554	-	38,403	83,203
Denning Chong ³	149,180	-	-	11,954	-	383,133	544,267
Executive Directors:							
Thomas Hanly ⁴	192,633	-	(10,260)	14,417	-	642,087	838,877
Prof. Kwang Guan Tay ⁵	77,019	-	-	5,432	-	84,191	166,642
Other Key Management Personnel:							
James Hill	137,077	-	(4,686)	14,393	-	235,260	382,044
Steven Wood ⁶	137,449	-	-	-	-	89,519	226,968
	794,415	-	(14,946)	49,750	-	1,510,996	2,340,215



¹\$4,604 of this amount is accrued and payable as at 30 June 2023.

 $^{\rm 2}$ \$7,400 of this amount is accrued and payable as at 30 June 2023.

³ This is the total amount paid to Denning for the period 1 Jul 2022 to 30 Jun 2023. Of the total amount \$63,109, cash salary and \$5,375 superannuation relate to amount paid to Denning in his capacity as Interim CEO and Managing Director. Of this amount \$35,334, is accrued and payable as at 30 June 2023.

⁴ Represents remuneration from 1 July 2022 to 14 April 2023.

⁵ Represents remuneration from 1 July 2022 to 24 March 2023.

⁶ Represents remuneration from 1 July 2022 to 24 March 2023.

The proportion of remuneration linked to performance and the fixed proportion are as follows:

	Fixed remuneration		At ris	k - STI	At risk - LTI		
Name	30 June 2024	30 June 2023	30 June 2024	30 June 2023	30 June 2024	30 June 2023	
Non-Executive Directors:							
Howard Digby	64%	61%	-	-	36%	39%	
Andrew Just	64%	54%	-	-	36%	46%	
Denning Chong	-	30%	-	-	-	70%	
Occutive Directors:							
Denning Chong	4%	-	17%	-	79%	-	
Ghomas Hanly	-	23%	-	-	-	77%	
Prof. Kwang Guan Tay	-	49%	-	-	-	51%	
Other Key Management Personnel:							
James Hill	52%	38%	-	-	48%	62%	
(K yla Garic	-	-	-	-	-	-	
Martina Mariano	70%	-	-	-	30%	-	
Steven Wood	-	60%	-	-	-	40%	

20.3 Service agreements

Executive Service Agreements

Bemuneration and other terms of employment for key management personnel are formalised in service agreements. Details of these agreements are as follows:

Name: Jitle: Agreement commenced: Term of agreement: Details:	Denning Chong Managing Director and Chief Executive Officer 15 April 2023 Termination by either party on notice of 4 months. Base salary including director fees for the year ending 30 June 2024 of \$250,000 per annum plus superannuation.
Name:	James Hill
Title:	Chief Operating Officer
Agreement commenced:	4 November 2019
	Variation letter dated 1 May 2024
Term of agreement:	Termination by either party on notice of 4 weeks.
Details:	Base salary for the year ending 30 June 2024 of \$161,000 per annum inclusive of superannuation.
Name:	Martina Mariano
Title:	Chief Commercial Officer
Agreement commenced:	9 February 2024
	Variation letter dated 1 May 2024
Term of agreement:	Termination by either party on notice of 4 weeks.
Details:	Base salary for the year ending 30 June 2024 of \$145,000 per annum inclusive of superannuation.



Non-executive directors

On appointment to the Board, all non-executive directors enter into a service agreement with the Group in the form of a letter of appointment. The letter summarises the Board's policies and terms, including compensation, relevant to the director, and among other things:

- the terms of the Directors' appointment, including governance, compliance with the Company's Constitution, committee appointments, and re-election.
- the Directors' duties, including disclosure obligations, exercising powers, use of office, attendance at meetings and commitment levels.
- the fees payable, in line with shareholder approval, any other terms, timing of payments and entitlements to reimbursements.
- insurance and indemnity.
- disclosure obligations; and
- confidentiality.

The following fees (exclusive of superannuation) applied during the financial year.

Name	Base salary
Mr. Howard Digby	\$50,000 \$40,000

10.4 Share-based compensation

Shares

There were no shares issued to Directors and other Key Management Personnel as part of compensation during the year ended 30 June 2024, however, the shares were issued to the Directors subsequent to 30 June 2024 which related to their 30 June 2024 services as per below.

Name	Date of issue	Shares	Issue price	\$
Andrew Just	25-Jul-2024	336,364	\$0.110	33,636
	25-Jul-2024	378,218	\$0.110	37,822

Options

The terms and conditions of each grant of options over ordinary shares affecting remuneration of Directors and other Key Management Personnel in this financial year or future reporting years are as follows:

O Name	Number of options granted	Grant date	Vesting date and exercisable date	Expiry date	Exercise price	Fair value per option at grant date
Denning Chong	11,250,000	10-Nov-23	10-Nov-23	10-Nov-27	\$0.080	\$0.0246
Andrew Just	1,000,000	10-Nov-23	10-Nov-23	10-Nov-27	\$0.080	\$0.0246
Howard Digby	1,250,000	10-Nov-23	10-Nov-23	10-Nov-27	\$0.080	\$0.0246
James Hill	2,000,000	10-Nov-23	10-Nov-23	10-Nov-27	\$0.080	\$0.0246
Martina Mariano	2,000,000	10-Nov-23	10-Nov-23	10-Nov-27	\$0.080	\$0.0246

Options granted carry no dividend or voting rights.

All options were granted over unissued fully paid ordinary shares in the company. The number of options granted was determined having regard to the satisfaction of performance measures and weightings as described above in the section '**Group performance and link to remuneration**'. Options vest based on the provision of service over the vesting period whereby the executive becomes beneficially entitled to the option on vesting date. Options are exercisable by the holder as from the vesting date. There has not been any alteration to the terms or conditions of the grant since the grant date. There are no amounts paid or payable by the recipient in relation to the granting of such options other than on their potential exercise.



Details of options over ordinary shares granted, vested and lapsed for Directors and other key management personnel as part of compensation during the year ended 30 June 2024 are set out below:

Name	Grant date	Financial years in which grant vest	Number of options granted	Value of options granted \$	Value of options vested \$	Number of options lapsed	Value of options lapsed \$
Denning Chong	10-Nov-23	30-June-24	11,250,000	276,773	276,773	-	-
Andrew Just	10-Nov-23	30-June-24	1,000,000	24,602	24,602	-	-
Howard Digby	10-Nov-23	30-June-24	1,250,000	30,753	30,753	-	-
James Hill	10-Nov-23	30-June-24	2,000,000	49,204	49,204	-	-
Martina Mariano	10-Nov-23	30-June-24	2,000,000	49,204	49,204	-	-

Performance rights

Details of performance rights over ordinary shares granted, vested and lapsed for Directors and other key management personnel as part of compensation during the year ended 30 June 2024 are set out below:

00		Financial years in which	Number of rights	Value of rights	Value of rights	Number of rights	Value of rights
N ame	Grant date	grant vest	granted	granted \$	vested \$	lapsed	lapsed \$
S							
Denning Chong	10-Nov-23	30-June-24	6,000,000	193,785	30,905	-	-
Denning Chong	12-Feb-21	lapsed during the year	-	-	-	1,200,000	240,000
James Hill	12-Feb-21	lapsed during the year	-	-	-	600,000	120,000
Dames Hill	10-Nov-23	30-June-24	2,000,000	64,595	10,302	-	-
James Hill	14-Dec-22	30-June-24	500,000	58,431	19,513	-	-
Martina Mariano	10-Nov-23	30-June-24	2,000,000	64,595	10,302	-	-
Games Hill	14-Dec-22	30-June-24	1,000,000	121,919	62,739	-	-
Denning Chong	12-Feb-21	30-June-24	1,200,000	240,000	71,183	-	-
Sames Hill	12-Feb-21	30-June-24	600,000	120,000	35,592	-	-
Denning Chong	28-Nov-22	30-June-24	1,000,000	132,870	44,330	-	-
Denning Chong	28-Nov-22	30-June-24	500,000	63,911	21,343	-	-

20.5 Additional information

The earnings of the Group for the four years to 30 June 2024 are summarised below:

	30 June 2024 \$	30 June 2023 \$	30 June 2022 \$	30 June 2021 \$
Revenue and other income from continuing operations	1,249,022	1,033,769	54,034	193,643
EBIT	(4,924,704)	(5,390,318)	(5,986,020)	(4,456,097)
Loss after income tax	(4,924,704)	(5,390,318)	(5,986,020)	(4,456,097)

The table below set out summary information about the Group's movement in shareholder wealth for the three years to 30 June 2024.

The factors that are considered to affect total shareholders return ('TSR') are summarised below:

	30 June 2024	30 June 2023	30 June 2022	30 June 2021
Share price at financial year end (\$)	0.10	0.03	0.09	0.31
Basic earnings per share (cents per share)	(3.08)	(4.90)	(5.83)	(6.02)
Diluted earnings per share (cents per share)	(3.08)	(4.90)	(5.83)	(6.02)

No dividends have been declared and paid for the year 30 June 2024 and 30 June 2023.



20.6 Additional disclosures relating to key management personnel

Shareholding

The number of shares in the Company held during the financial year by each Director and other members of Key Management Personnel of the Group, including their personally related parties, is set out below:

Ordinary shares	Balance at the start of the year	Received as part of remuneration	Additions	Disposals/ other	Balance at the end of the year
Directors					
Denning Chong	6,877,800	-	930,775	-	7,808,575
Andrew Just	-	-	-	-	-
Howard Digby	302,391	-	-	-	302,391
Key Management Personnel					
James Hill	847,391	-	-	-	847,391
Kyla Garic ¹	-	-	-	-	-
Martina Mariano ¹	×	-	-	-	-
	8,027,582	-	930,775	-	8,958,357

Che number of options over ordinary shares in the Company held during the financial year by each Director and other members of key management personnel of the Group, including their personally related parties, is set out below:

nS	Balance at the start of			Expired/ forfeited/	Balance at the end of
Options over ordinary shares	the year	Granted	Exercised	other	the year
Directors					
CDenning Chong	6,318,182	11,250,000	-	-	17,568,182
Andrew Just	1,000,000	1,000,000	-	-	2,000,000
Howard Digby	1,000,000	1,250,000	-	-	2,250,000
Key Management Personnel					
Chames Hill	2,650,000	-	-	-	2,650,000
K yla Garic ¹	-	-	-	-	-
Martina Mariano ¹	100,000	2,000,000	-	-	2,100,000
Ō	11,068,182	15,500,000	-	-	26,568,182

Performance rights holding

The number of performance rights over ordinary shares in the Company held during the financial year by each Director and other members of key management personnel of the Group, including their personally related parties, is set out below:

Performance rights over ordinary shares	Balance at the start of the year	Granted	Vested	Expired/ forfeited/ other	Balance at the end of the year
Directors					
Denning Chong	3,900,000	6,000,000	-	(1,200,000)	8,700,000
Andrew Just	-	-	-	-	-
Howard Digby	-	-	-	-	-
Key Management Personnel	-	-	-	-	-
James Hill	2,700,000	-	-	(600,000)	2,100,000
Kyla Garic ¹	-	-	-	-	-
Martina Mariano ¹	-	2,000,000	-	-	2,000,000
	-	-	-	-	-
	6,600,000	8,000,000	-	(1,800,000)	12,800,000

¹ Balance start at date of appointment as Key Management Personnel.



Loans to key management personnel and their related parties

No loans were provided to, made, guaranteed or secured directly or indirectly to any KMP or their related entities during the financial year.

Other transactions with key management personnel and their related parties

Re-Energise Digital, a company associated with James Hill, received \$2,106 excluding GST in fees (30 June 2023: \$19,064) during the year for marketing services provided to the Company, with \$nil payable at 30 June 2024.

Grange Consulting Group Pty Ltd, of which Steven Wood was a Director for part of the period, received \$86,400 excluding GST (30 June 2023: \$137,494) during the year for financial services, company secretarial work and corporate advisory services. These services are provided on normal commercial terms and at arm's length, with nil balance payable as at 30 June 2024.

Onyx Corporate Pty Ltd, of which Kyla Garic is a Director, received \$65,000 excluding GST (30 June 2023: \$nil) during the year for corporate financial services. These services are provided on normal commercial terms and at arm's length, with nil balance payable as at 30 June 2024.

This concludes the remuneration report, which has been audited.

This report is made in accordance with a resolution of Directors, pursuant to section 298(2)(a) of the Corporations Act 2001.

On behalf of the Directors



nexia.com.au

To the Board of Directors of Singular Health Group Limited

Auditor's Independence Declaration under section 307C of the Corporations Act 2001

As lead auditor for the audit of the financial statements of Singular Health Group Limited for the year ended 30 June 2024, I declare that to the best of my knowledge and belief, there have been no contraventions of:

- (a) the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
- (b) any applicable code of professional conduct in relation to the audit.

Yours sincerely

NPAS

Nexia Perth Audit Services Pty Ltd

a. Il

Justin Mulhair Director

Perth, Western Australia 29 August 2024

Advisory. Tax. Audit.

ACN 145 447 105

Nexia Perth Audit Services Pty Ltd (ABN 27 145 447 105) is a firm of Chartered Accountants. It is affiliated with, but independent from Nexia Australia Pty Ltd. Nexia Australia Pty Ltd is a member of Nexia International, a leading, global network of independent accounting and consulting firms. For more information please see www.nexia.com. au/legal. Neither Nexia International nor Nexia Australia Pty Ltd provide services to clients.

Singular Health Group Limited and its controlled entities Consolidated statement of profit or loss and other comprehensive income For the year ended 30 June 2024



	Note	30 June 2024 \$	30 June 2023 \$
Revenue from continuing operations	5	90,825	28,122
Research and development grant income	6	843,249	414,219
Interest revenue calculated using the effective interest method		11,673	3,221
Other income		1,102	-
Finance income	22	302,173	-
Expenses			
Patent, research and development expenses	7	(417,713)	(587,740)
Consultancy and subcontractor fees		(300,421)	(244,505)
Employee and director benefits expenses	8	(1,078,938)	(1,655,910)
Corporate and legal expenses	9	(218,159)	(523,195)
Selling and marketing expenses		(290,836)	(61,870)
Depreciation and amortisation expense		(197,695)	(268,856)
Impairment of investments		(4,575)	(164,825)
Share-based payments	11	(1,186,081)	(1,267,114)
Share of net loss in associates		-	(8,205)
Administrative expenses		(306,378)	(187,994)
Cother expenses		(28,883)	(14,673)
G inance costs		(97,789)	(433,543)
		(- / /	(//
Loss before income tax expense from continuing operations		(2,878,446)	(4,972,868)
Come tax expense	12		-
oss after income tax expense from continuing operations		(2,878,446)	(4,972,868)
Solution Sector Continued Operations	4	(2,046,258)	(417,450)
boss after income tax expense for the year attributable to the owners of Singular Health roup Limited		(4,924,704)	(5,390,318)
Souther comprehensive income			
Items that may be reclassified subsequently to profit or loss			
Foreign currency translation		7,044	(101)
Other comprehensive income for the year, net of tax		7,044	(101)
Total comprehensive income for the year attributable to the owners of Singular Health Group Limited		(4,917,660)	(5,390,419)
Total comprehensive income for the year is attributable to: Continuing operations Discontinued operations		(4,917,660)	(5,390,419) -
		(4,917,660)	(5,390,419)

Singular Health Group Limited and its controlled entities Consolidated statement of profit or loss and other comprehensive income For the year ended 30 June 2024



		Cents	Cents
Earnings per share for loss from continuing operations attributable to the owners of			
Singular Health Group Limited			
Basic earnings per share	10	(1.80)	(4.52)
Diluted earnings per share	10	(1.80)	(4.52)
Earnings per share for loss from discontinued operations attributable to the owners o	F		
Singular Health Group Limited			
Basic earnings per share	10	(1.28)	(0.38)
Diluted earnings per share	10	(1.28)	(0.38)
Earnings per share for loss attributable to the owners of Singular Health Group Limited	3		
Basic earnings per share	10	(3.08)	(4.90)
Diluted earnings per share	10	(3.08)	(4.90)

Singular Health Group Limited and its controlled entities **Consolidated statement of financial position** As at 30 June 2024



	30 June 2024 \$	30 June 2023 \$
Assets		
Current assets		
Cash and cash equivalents 13	1,453,360	691,513
Trade and other receivables 15	62,645	76,186
Inventories	-	129,287
Other assets	47,096	86,412
	1,563,101	983,398
Assets of disposal groups classified as held for sale 17	636,251	-
Total current assets	2,199,352	983,398
Non-current assets		
Investments accounted for using the equity method 18	-	70,000
Property, plant and equipment 19	37,742	740,335
Right-of-use assets16	-	128,678
Thtangibles 20	113,699	1,046,547
Souther assets		29,618
Dotal non-current assets	151,441	2,015,178
Cotal assets	2,350,793	2,998,576
Liabilities		
W urrent liabilities		
Trade and other payables 21	315,677	333,392
Contract liabilities	4,531	6,633
Borrowings 22	218,453	2,236,000
Clease liabilities 23	-	42,086
Provisions	109,917	86,147
\mathbf{O}	648,578	2,704,258
Diabilities directly associated with assets classified as held for sale 24	261,007	-
Total current liabilities	909,585	2,704,258
On-current liabilities		
Borrowings 22	-	139,611
Lease liabilities 23		92,815
Total non-current liabilities		232,426
Total liabilities	909,585	2,936,684
Net assets	1,441,208	61,892
Equity		
Issued capital 25	16,430,777	11,977,564
Reserves 26	5,913,988	4,221,834
Accumulated losses	(20,903,557)	(16,137,506)
Total equity	1,441,208	61,892

Singular Health Group Limited and its controlled entities Consolidated statement of changes in equity For the year ended 30 June 2024



	Issued capital \$	Share-based payment reserves \$	Foreign currency translation reserve \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2022	9,526,669	3,376,290	(4,552)	(11,149,705)	1,748,702
Loss after income tax expense for the year Other comprehensive income for the year, net of	-	-	-	(5,390,318)	(5,390,318)
tax			(101)		(101)
Total comprehensive income for the year	-	-	(101)	(5,390,318)	(5,390,419)
Transactions with owners in their capacity as owners: Contributions of equity, net of transaction costs (note 25) Share-based payments (note 11) Expired options	2,378,895 72,000 -	- 1,252,714 (402,517)	- - -	- - 402,517	2,378,895 1,324,714 -
Balance at 30 June 2023	11,977,564	4,226,487	(4,653)	(16,137,506)	61,892
nal u	Issued capital \$	Share-based payment reserve \$	Foreign currency translation reserve \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2023	11,977,564	4,226,487	(4,653)	(16,137,506)	61,892
boss after income tax expense for the year ther comprehensive income for the year, net of tax	-	-	- 7,044	(4,924,704)	(4,924,704) 7,044
Total comprehensive income for the year	-	-	7,044	(4,924,704)	(4,917,660)
Transactions with owners in their capacity as owners: Contributions of equity, net of transaction costs					
(note 25) Share-based payments (note 11)	4,624,086	467,704 1,285,081	-	-	5,091,790 1,285,081
Exercised of options Fair value adjustment on business combination	- 76,627	1,203,001 -	-	-	76,627
(note 29)	(247,500)	90,978	-	-	(156,522)
Exercised of performance rights	-	(37,176)	-	37,176	-
Options lapsed	-	(121,477)	-	121,477	-
Balance at 30 June 2024	16,430,777	5,911,597	2,391	(20,903,557)	1,441,208

Singular Health Group Limited and its controlled entities **Consolidated statement of cash flows** For the year ended 30 June 2024



	Note	30 June 2024 \$	30 June 2023 \$
Cash flows from operating activities			
Receipts from customers (inclusive of GST)		1,094,373	688,074
Payments to suppliers and employees (inclusive of GST)		(4,521,520)	(3,508,366)
Interest received		8,498	3,406
Government grants received		978,360	414,217
Net cash used in operating activities	14	(2,440,289)	(2,402,669)
Cash flows from investing activities			
Payment for purchase of business, net of cash acquired	29	-	(612,725)
Payments for property, plant and equipment		(73,559)	(22,489)
Proceeds from disposal of joint venture		70,000	-
Net cash used in investing activities		(3,559)	(635,214)
C			
sh flows from financing activities			
Proceeds from issue of shares	25	5,168,411	1,553,895
Rroceeds from issue of convertible notes		-	800,000
Proceeds from borrowings		811,698	419,236
Un terest and other finance costs paid		(258,281)	(60,516)
Bepayment of borrowings		(2,482,774)	-
Repayment of lease liabilities		(31,477)	(123,067)
Concepted to the second		3,207,577	2,589,548
Net increase/(decrease) in cash and cash equivalents		763,729	(448,335)
Cash and cash equivalents at the beginning of the financial year		691,513	1,139,935
Ceffects of exchange rate changes on cash and cash equivalents			(87)
Cash and cash equivalents at the end of the financial year	13	1,455,242	691,513
0			
C			
\smile			





Note 1. Material accounting policy information	32
Note 2. Critical accounting judgements, estimates and assumptions	34
Note 3. Operating segments	36
Note 4. Discontinued operations	37
Note 5. Revenue	38
Note 6. Research and development grant income	39
Note 7. Patent, research and development expenses	39
Note 8. Employee and director benefits expenses	39
Note 9. Corporate, audit and legal expenses	40
Note 10. Earnings per share	40
Note 11. Share-based payments	41
Note 12. Income tax	47
Note 13. Cash and cash equivalents	49
Note 14. Cash flow information	50
Note 15. Trade and other receivables	51
Note 16. Right-of-use assets	51
Note 17. Assets of disposal groups classified as held for sale	52
Solution of the equity of the equity method set of the equity method se	53
Note 19. Property, plant and equipment	54
General Content of the second se	55
Note 21. Trade and other payables	56
Note 22. Borrowings	56
Note 23. Lease liabilities	58
Note 24. Liabilities directly associated with assets classified as held for sale	59
🕠 ote 25. Issued capital	59
Note 26. Reserves	60
Note 27. Financial instruments	63
Note 28. Fair value measurement	65
Note 29. Business combinations	65
Note 30. Key management personnel disclosures	68
Note 31. Related party transactions	68
Note 32. Commitments and contingent liabilities	69
Note 33. Parent entity information	70
Note 34. Interests in subsidiaries	71
Note 35. Interests in joint operations	71
Note 36. Events after the reporting period	72

Singular Health Group Limited and its controlled entities Notes to the consolidated financial statements 30 June 2024



Note 1. Material accounting policy information

The accounting policies that are material to the Group are set out either in the respective notes or below. The accounting policies adopted are consistent with those of the previous financial year, unless otherwise stated.

(a) Basis of preparation

These general-purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the *Corporations Act 2001*, as appropriate for for-profit oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

Historical cost convention

The financial statements have been prepared under the historical cost convention.

Critical accounting estimates

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in **note 2**.

(b) Going concern

These financial statements have been prepared on a going concern basis, which contemplates the continuity of normal business activities and the realisation of assets and settlement of liabilities in the normal course of business.

As disclosed in the financial report, the Group recorded an operating loss of \$4,924,704 (30 June 2023: \$5,390,318) and a cash outflow from operating activities of \$2,440,289 for the year ended 30 June 2024 (30 June 2023: \$2,402,669). As at 30 June 2024, the Group had ash and cash equivalents of \$1,453,360 (30 June 2023: \$691,513) and had a working capital surplus of \$1,289,767 (30 June 2023: deficit 1,720,860). The ability of the Group to continue as a going concern is principally dependent upon the ability of the Group to continue to secure funds by raising capital from equity markets, monetizing non-core assets and managing cash flows in line with available funds.

should the Group be unsuccessful in securing additional funds or monetizing non-core assets, there is a material uncertainty that may east significant doubt about the Group's ability to continue as a going concern, however, notwithstanding this, the accounts have been prepared on a going concern basis.

The Directors are satisfied that at the date of signing of the financial report, there are reasonable grounds to believe that the Group will be able to continue to meet its debts as and when they fall due and that it is appropriate for the financial statements to be prepared on a going concern basis.

The Directors have based this on the following pertinent matters:

- The Directors believe that future funding will be available to meet the Group's objectives and debts as and when they fall due, including through raising additional capital through equity placements to existing or new investors. The Company has demonstrated a consistent history of success in this regard as demonstrated by the AUD\$4.1m raising completed in February 2024 and a subsequent raised of AUD\$1 million;
- The Company has approved capacity to issue additional equity under the Corporation Act 2001 and ASX Listing Rule 7.1 or otherwise;
- The Group has the capacity, if necessary, to reduce its operating cost structure in order to minimise its working capital requirements; and
- Subject to successful capital raising and/or monetisation of non-core assets, the cash flow forecast for the period to 31 October 2025 indicates sufficient cash available for planned activities and operations.

The financial report does not include adjustments relating to the recoverability or classification of the recorded assets nor to the amounts or classification of liabilities that might be necessary should the Group not be able to continue as a going concern.

Should the Group be unable to continue as a going concern, it may be required to realise its assets and extinguish its liabilities other than in the normal course of business and at the amounts stated in the financial report. The financial report does not include any adjustments relating to the recoverability and classification of recorded asset amounts or to the amounts and classification of liabilities that might be necessary should the Group not continue as a going concern.



Note 1. Material accounting policy information (continued)

(c) New or amended Accounting Standards and Interpretations adopted

The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. These Standards, amendments or interpretations are not expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.

(d) Principles of consolidation

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Singular Health Group Limited ('Company' or 'parent entity') as at 30 June 2024 and the results of all subsidiaries for the year then ended. Singular Health Group Limited and its subsidiaries together are referred to in these financial statements as the 'Group'.

Subsidiaries are all those entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date from the date that control ceases.

The second part of the second provides and unrealised gains on transactions between entities in the Group are eliminated. Unrealised second provides are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.

The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the ss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value f the share of the non-controlling interest acquired is recognised directly in equity attributable to the parent.

Where the Group loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and non-controlling interest in the subsidiary together with any cumulative translation differences recognised in equity. The Group recognises the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss.

(Ue) Parent entity information

b accordance with the Corporations Act 2001, these financial statements present the results of the Group only. Supplementary information about the parent entity is disclosed in **note 33**.

(f) Foreign currency translation

The financial statements are presented in Australian dollars, which is Singular Health Group Limited's functional and presentation currency.

Foreign currency transactions

Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at financial year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss.

Foreign operations

The assets and liabilities of foreign operations are translated into Australian dollars using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Australian dollars using the average exchange rates, which approximate the rates at the dates of the transactions, for the period. All resulting foreign exchange differences are recognised in other comprehensive income through the foreign currency reserve in equity.

The foreign currency reserve is recognised in profit or loss when the foreign operation or net investment is disposed of.

(g) Current and non-current classification

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.



Note 1. Material accounting policy information (continued)

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the Group's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the Group's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

Deferred tax assets and liabilities are always classified as non-current.

(h) Interest

Interest income is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

(i) Finance costs

Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in the period in which they are incurred.

(Goods and Services Tax ('GST') and other similar taxes

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position.

Seash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.

Note 2. Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Share-based payment transactions

The Group measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using either the Binomial or Black-Scholes model taking into account the terms and conditions upon which the instruments were granted detailed within **note 11**. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.

Allowance for expected credit losses

The allowance for expected credit losses assessment requires a degree of estimation and judgement. It is based on the lifetime expected credit loss, grouped based on days overdue, and makes assumptions to allocate an overall expected credit loss rate for each group. These assumptions include recent sales experience and historical collection rates.



Note 2. Critical accounting judgements, estimates and assumptions (continued)

Provision for impairment of inventories

The provision for impairment of inventories assessment requires a degree of estimation and judgement. The level of the provision is assessed by taking into account the recent sales experience, the ageing of inventories and other factors that affect inventory obsolescence.

Fair value measurement hierarchy

The Group is required to classify all assets and liabilities, measured at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date; Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3: Unobservable inputs for the asset or liability. Considerable judgement is required to determine what is significant to fair value and therefore which category the asset or liability is placed in can be subjective.

The fair value of assets and liabilities classified as level 3 is determined by the use of valuation models. These include discounted cash flow analysis or the use of observable inputs that require significant adjustments based on unobservable inputs.

Estimation of useful lives of assets

Che Group determines the estimated useful lives and related depreciation and amortisation charges for its property, plant and equipment and finite life intangible assets. The useful lives could change significantly as a result of technical innovations or some other event. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

Goodwill and other indefinite life intangible assets

The Group tests annually, or more frequently if events or changes in circumstances indicate impairment, whether goodwill and other to definite life intangible assets have suffered any impairment, in accordance with the accounting policy stated in **note 20**. The recoverable amounts of cash-generating units have been determined based on value-in-use calculations. These calculations require the use of assumptions, including estimated discount rates based on the current cost of capital and growth rates of the estimated future ash flows.

Limpairment of non-financial assets other than goodwill and other indefinite life intangible assets

The Group assesses impairment of non-financial assets other than goodwill and other indefinite life intangible assets at each reporting date by evaluating conditions specific to the Group and to the particular asset that may lead to impairment. If an impairment trigger exists, the recoverable amount of the asset is determined. This involves fair value less costs of disposal or value-in-use calculations, which incorporate a number of key estimates and assumptions.

Impairment of property, plant and equipment

The Group assesses impairment of property, plant and equipment at each reporting date by evaluating conditions specific to the Group and to the particular asset that may lead to impairment. If an impairment trigger exists, the recoverable amount of the asset is determined. This involves fair value less costs of disposal or value-in-use calculations, which incorporate a number of key estimates and assumptions.

Income tax

ഗ

The Group is subject to income taxes in the jurisdictions in which it operates. Significant judgement is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The Group recognises liabilities for anticipated tax audit issues based on the Group's current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.

Business combinations

As discussed in **note 29**, business combinations are initially accounted for on a provisional basis. The fair value of assets acquired, liabilities and contingent liabilities assumed are initially estimated by the Group taking into consideration all available information at the reporting date. Fair value adjustments on the finalisation of the business combination accounting is retrospective, where applicable, to the period the combination occurred and may have an impact on the assets and liabilities, depreciation and amortisation reported.



Note 2. Critical accounting judgements, estimates and assumptions (continued)

Discontinued Operations

Management has taken into consideration of the application of AASB 5 Non-current Assets Held for Sale and Discontinued Operations, specifically **par 6-8**, refer to **note 4** for further information.

Key criteria that met the classification under **AASB 5** as below:

1. Immediate Sale Availability

The assets of the company in the state of available for immediate sale without significant delay.

2. High Probability of Sale

- The sale of the asset is highly probably within the next twelve months. This probability Is assessed based on the factors such as Management's commitment to the sale (approved by the board), ceased one of the major machinery sales, absence of employees in the Company and have identification of a potential buyer.

3. Fair Value Measurements

The asset measured at the lower of its carrying value and fair value less costs to sell. Fair value represents the amount that could be obtained from selling the asset in an open market transaction.

Note 3. Operating segments

Segment information has been prepared in conformity with the accounting policies adopted for preparing and presenting the financial statements of the Group. The Group's primary business segment is the provision of Volume Rendering Platform (VRP) software, providing advanced 3D printing services and 3D machine sales. During the year, the Group closed down the machine sales division. The Group perates in one segment, which is the provision and development of medical technology within Australia.

An operating segment is a component of an entity that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity), whose operating results are regularly reviewed by the chief operating decision makers - being the executive management team to make decisions about resources be allocated to the segment and assess its performance and for which discrete financial information is available. This includes start-up operations which are yet to earn revenues.

Management will also consider other factors in determining operating segments such as the existence of a line manager and the level of segment information presented to the board of directors. Operating segments have been identified based on the information provided to the chief operating decision makers – being the executive management team.

The Group aggregates two or more operating segments when they have similar economic characteristics, and the segments are similar in the nature of medical technology targeted. Operating segments that meet the quantitative criteria as prescribed by AASB 8 are reported separately. However, an operating segment that does not meet the quantitative criteria is still reported separately where formation about the segment would be useful to users of the financial statements. Information about other business activities and operating segments that are below the quantitative criteria are combined and disclosed in a separate category for "all other segments". The chief operating decision maker has been identified as the Board of Directors.



Note 4. Discontinued operations

Management is actively seeking potential buyers for Singular 3DP Pty Ltd, following a strategic decision to place greater focus on the Group's key competency - i.e. medical software development and commercialisation and given the rapid traction being achieved by the Company for its software applications.

The assets groups were not previously classified as held for sale or as a discontinued operation. The comparative consolidated statement of profit or loss and OCI has been re-presented to show the discontinued operation separately from continuing operations. *Financial performance information*

	30 June 2024 \$	30 June 2023 \$
Stripe sales	12,748	116
Consumable sales	2,131	4,213
3D machinery sales	865,342	541,780
3D printing sales	90,654	41,911
Discontinued revenue	970,875	588,020
Research and development grant income	134,010	-
Interest income	156	187
biscontinued total other income	134,166	187
Cost of sales	(997,681)	(514,496)
Patent, research and development expenses	(10,850)	-
Consultancy and subcontractor fees	(82,841)	(7,970)
Remployee and director benefit expenses	(338,694)	(169,392)
Corporate, audit and legal expenses	(25,430)	(3,743)
epreciation and amortisation	(309,563)	(120,290)
Administration expenses	(58,139)	(96,956)
Share-based payments	(99,000)	-
Interest expenses	(85,094)	(43,843)
Umpairment expenses	(975,660)	-
Transaction expenses	(86,364)	-
Written off	(33,238)	-
Allowance for credit loss	(17,675)	-
Other expenses	(31,070)	(48,967)
Discontinued total expenses	(3,151,299)	(1,005,657)
Loss before income tax expense Income tax expense	(2,046,258)	(417,450)
Loss after income tax expense from discontinued operations	(2,046,258)	(417,450)

Cash flow information

l

	30 June 2024 \$
Net cash used in operating activities	(834,447)
Net cash used in investing activities	(44,395)
Net cash from financing activities	823,218
Net decrease in cash and cash equivalents from discontinued operations	(55,624)

Singular Health Group Limited and its controlled entities Notes to the consolidated financial statements 30 June 2024



Note 4. Discontinued operations (continued)

Accounting policy for discontinued operations

A discontinued operation is a component of the Group that has been disposed of or is classified as held for sale and that represents a separate major line of business or geographical area of operations, is part of a single co-ordinated plan to dispose of such a line of business or area of operations, or is a subsidiary acquired exclusively with a view to resale. The results of discontinued operations are presented separately on the face of the statement of profit or loss and other comprehensive income.

Note 5. Revenue

Disaggregation of revenue

The disaggregation of revenue from contracts with customers is as follows:

30 June 2024	Product sales \$	Stripe sales \$	Printing sales \$	Total \$
Geographical regions				
Australia	21,705	49,980	-	71,685
Rest of the world	19,140	-	-	19,140
Otal	40,845	49,980	_	90,825
D iming of revenue recognition				
Goods transferred at a point in time	38,997	49,980	-	88,977
Services rendered over time	1,848	-	-	1,848
Total	40,845	49,980	-	90,825
O (30 June 2023	Product sales \$	Stripe sales \$	Printing sales \$	Total \$
		•	· ·	
Geographical regions				
Australia	893	1,707	-	2,600
Best of the world		25,522	-	25,522
Total	893	27,229	-	28,122
Timing of revenue recognition				
Goods transferred at a point in time Services rendered over time	893	27,229	-	28,122
Total	893	27,229	-	28,122

Accounting policy for revenue recognition

The Group recognises revenue as follows:

Revenue from contracts with customers

Revenue is recognised at an amount that reflects the consideration to which the Group is expected to be entitled in exchange for transferring goods or services to a customer. For each contract with a customer, the Group: identifies the contract with a customer; identifies the performance obligations in the contract; determines the transaction price which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good or service to be delivered; and recognises revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services promised.

Singular Health Group Limited and its controlled entities Notes to the consolidated financial statements 30 June 2024



Note 5. Revenue (continued)

Variable consideration within the transaction price, if any, reflects concessions provided to the customer such as discounts, rebates and refunds, any potential bonuses receivable from the customer and any other contingent events. Such estimates are determined using either the 'expected value' or 'most likely amount' method. The measurement of variable consideration is subject to a constraining principle whereby revenue will only be recognised to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The measurement constraint continues until the uncertainty associated with the variable consideration is subsequently resolved. Amounts received that are subject to the constraining principle are recognised as a refund liability.

Sale of goods

Revenue from the sale of goods is recognised at the point in time when the customer obtains control of the goods, which is generally at the time of delivery.

Rendering of services

Revenue from a contract to provide services is recognised over time as the services are rendered based on either a fixed price or an hourly rate.

Note 6. Research and development grant income

S	30 June 2024	30 June 2023
C	\$	\$
Government grants	843,249	414,219

Accounting policy for research and development grant

&D refunds are a tax offset under the R&D tax incentive recognised on receipt of funds from the Australian Taxation Office for research and development expenditure incurred in the previous financial year. They are presented in the statement of profit and loss and other comprehensive income as other income.

Note 7. Patent, research and development expenses

00	30 June 2024 \$	30 June 2023 \$
Quality accreditation	80,340	172,825
O ther expenses	12,252	21,179
Research and development	325,121	393,736
Total patent, research and development expenses	417,713	587,740

Note 8. Employee and director benefits expenses

	30 June 2024 \$	30 June 2023 \$
Other employee expenses (including superannuation) Employee wages and directors' fees	205,531 873,407	152,817 1,503,093
Total employee benefits expense	1,078,938	1,655,910

Note 9. Corporate and legal expenses



	30 June 2024 \$	30 June 2023 \$
Legal expenses Corporate expenses	106,628 111,531	71,157 452,038
Total corporate and legal expenses	218,159	523,195
Note 10. Earnings per share		
	30 June 2024 \$	30 June 2023 \$
Cornings per share for loss from continuing operations	(2,878,446)	(4,972,868)
Ō	Cents	Cents
Basic earnings per share	(1.80) (1.80)	(4.52) (4.52)
	30 June 2024 \$	30 June 2023 \$
Rearnings per share for loss from discontinued operations	ę	Ŷ
Loss after income tax attributable to the owners of Singular Health Group Limited	(2,046,258)	(417,450)
S	Cents	Cents
Basic earnings per share Biluted earnings per share	(1.28) (1.28)	(0.38) (0.38)
O L	30 June 2024 \$	30 June 2023 \$
Loss after income tax attributable to the owners of Singular Health Group Limited	(4,924,704)	(5,390,318)
	Cents	Cents
Basic earnings per share Diluted earnings per share	(3.08) (3.08)	(4.90) (4.90)
	Number	Number
Weighted average number of ordinary shares Weighted average number of ordinary shares used in calculating basic earnings per share	160,145,633	109,970,902
Weighted average number of ordinary shares used in calculating diluted earnings per share	160,145,633	109,970,902

Singular Health Group Limited and its controlled entities Notes to the consolidated financial statements 30 June 2024



Note 10. Earnings per share (continued)

Accounting policy for earnings per share

Basic earnings per share

Basic earnings per share is calculated by dividing the profit attributable to the owners of Singular Health Group Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year.

Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

Note 11. Share-based payments

	Note	30 June 2024 \$	30 June 2023 \$
Share-based payments from continuing operations		1,186,081	1,267,114
Share-based payment from discontinuing operations ¹	4	99,000	
<u> </u>		1,285,081	1,267,114
¹ On 27 June 2024, the shareholders granted 1,000,000 ordinary share	s valued at \$0.099 to Nigel Bro		

¹ On 27 June 2024, the shareholders granted 1,000,000 ordinary shares valued at \$0.099 to Nigel Brown as mutual agreement signed between the parties during the year, and the equities were issued subsequent to 30 June 2024. Share-based payment of \$99,000 ecognised during the year.

options

share option plan has been established by the Group and approved by shareholders at a general meeting, grant options over ordinary shares in the Company to certain key management personnel of the Group. The options are issued for nil consideration and are granted in accordance with performance guidelines established by the Company.

Set out below are summaries of options granted under the plan:

	Number of options 30 June 2024	Weighted average exercise price 30 June 2024	Number of options 30 June 2023	Weighted average exercise price 30 June 2023
Outstanding at the beginning of the financial year	32,580,000	\$0.097	22,780,000	\$0.031
Granted	28,000,000	\$0.041	9,800,000	\$0.066
Expired	(1,000,000)	\$0.170	-	\$0.000
Outstanding at the end of the financial year	59,580,000	\$0.138	32,580,000	\$0.097



30 June 2024

			Balance at			Expired/	Balance at
		Exercise	the start of			forfeited/	the end of
Grant date	Expiry date	price	the year	Granted	Exercised	other	the year
10/11/2023	11/11/2027	\$0.008	-	19,500,000	-	-	19,500,000
27/06/2024	26/06/2027	\$0.150	-	8,500,000 ¹	-	-	8,500,000
12/02/2021	12/02/2025	\$0.300	19,250,000	-	-	-	19,250,000
23/11/2021	20/12/2025	\$0.300	1,670,000	-	-	-	1,670,000
23/11/2021	20/12/2025	\$0.300	20,000	-	-	-	20,000
23/11/2021	20/12/2025	\$0.300	300,000	-	-	-	300,000
23/11/2021	20/12/2025	\$0.300	40,000	-	-	-	40,000
23/11/2021	12/02/2025	\$0.300	250,000	-	-	-	250,000
23/11/2021	12/02/2025	\$0.300	250,000	-	-	-	250,000
22/12/2021	10/01/2024	\$0.400	300,000	-	-	(300,000)	-
22/12/2021	10/01/2024	\$0.500	300,000	-	-	(300,000)	-
22/12/2021	10/01/2024	\$0.600	400,000	-	-	(400,000)	-
03/08/2022	19/08/2024	\$0.240	800,000	-	-	-	800,000
28/11/2022	23/12/2025	\$0.400	5,000,000	-	-	-	5,000,000
16/06/2023	26/06/2026	\$0.100	3,500,000	-	-	-	3,500,000
16/06/2023	26/06/2026	\$0.100	500,000	-	-	-	500,000
n			32,580,000	28,000,000	-	(1,000,000)	59,580,000

¹ On 27 June 2024, the shareholders granted 8,500,000 options to Brokers valued at \$0.055 as mandate signed between the parties wring the year, the equities were issued subsequent to 30 June 2024. Capital raising cost of \$467,702 recognised during the year.

The weighted average share price during the financial 30 June 2024 was \$0.073 (30 June 2023: \$0.098).

The weighted average remaining contractual life of options outstanding at the end of the financial 30 June 2024 was 1.4 years (30 June 2023: 1.86 years).

The options granted during the current financial year, the Black-Scholes valuation model inputs used to determine the fair value at the grant date, are as follows:

Grant date	Expiry date	Share price at grant date	Exercise price	Expected volatility	Dividend yield	Risk-free interest rate	Fair value at grant date
10/11/2023	11/11/2027	\$0.041	\$0.080	100.00%	-	4.30%	\$0.0246
27/06/2024	26/07/2027	\$0.150	\$0.099	100.00%		4.16%	\$0.0500

Performance rights

Set out below are summaries of performance rights granted under the plan:

	Number of rights 30 June 2024	Weighted average exercise price 30 June 2024	Number of rights 30 June 2023	Weighted average exercise price 30 June 2023
Outstanding at the beginning of the financial year	16,900,000	\$0.000	10,000,000	\$0.000
Granted	19,288,877	\$0.000	6,900,000	\$0.000
Exercised	(588,877)	\$0.000	-	\$0.000
Expired	(5,000,000)	\$0.000		\$0.000
Outstanding at the end of the financial year	30,600,000	\$0.000	16,900,000	\$0.000



30 June 2024

		Exercise	Balance at the start of			Expired/ forfeited/	Balance at the end of
Grant date	Expiry date	price	the year	Granted	Exercised	other	the year
Grant date		price	the year	Grantea	Excitized	other	the year
12/02/2021	31/12/2023	\$0.000	5,000,000	-	-	(5,000,000)	-
12/02/2021	31/12/2024	\$0.000	5,000,000	-	-	-	5,000,000
14/12/2022	14/12/2025	\$0.000	2,600,000	-	-	-	2,600,000
28/11/2022	29/11/2025	\$0.000	2,000,000	-	-	-	2,000,000
14/12/2022	14/12/2025	\$0.000	1,300,000	-	-	-	1,300,000
28/11/2022	29/11/2025	\$0.000	1,000,000	-	-	-	1,000,000
20/09/2023	20/09/2025	\$0.000	-	4,500,000	-	-	4,500,000
10/11/2023	10/11/2027	\$0.000	-	1,600,000	-	-	1,600,000
10/11/2023	10/11/2027	\$0.000	-	12,000,000	(400,000)	-	11,600,000
21/02/2024	01/11/2023	\$0.000	-	188,877	(188,877)	-	-
27/06/2024	09/01/2026	\$0.000	-	1,000,000 ¹	-	-	1,000,000
5			16,900,000	19,288,877	(588,877)	(5,000,000)	30,600,000
The performa	ince rights were app	roved by sharehol	ders on 27 June 2	024 but were iss	ued after the fina	incial year.	
د ۲	0 11						
30 June 2023							
			Balance at			Expired/	Balance at
\square		Exercise	the start of			forfeited/	the end of
Grant date	Expiry date	price	the year	Granted	Exercised	other	the year

Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
24/42/2022	¢0.000	F 000 000				5 000 000
31/12/2023	\$0.000	5,000,000	-	-	-	5,000,000
31/12/2024	\$0.000	5,000,000	-	-	-	5,000,000
14/12/2025	\$0.000	-	2,600,000	-	-	2,600,000
28/11/2025	\$0.000	-	2,000,000	-	-	2,000,000
14/12/2025	\$0.000	-	1,300,000	-	-	1,300,000
28/11/2025	\$0.000	-	1,000,000	-	-	1,000,000
		10,000,000	6,900,000	-	-	16,900,000
	31/12/2023 31/12/2024 14/12/2025 28/11/2025 14/12/2025	Expiry date price 31/12/2023 \$0.000 31/12/2024 \$0.000 14/12/2025 \$0.000 28/11/2025 \$0.000 14/12/2025 \$0.000	Expiry dateExercise pricethe start of the year31/12/2023\$0.0005,000,00031/12/2024\$0.0005,000,00014/12/2025\$0.000-28/11/2025\$0.000-28/11/2025\$0.000-28/11/2025\$0.000-28/11/2025\$0.000-28/11/2025\$0.000-	Expiry dateExercise pricethe start of the yearGranted31/12/2023\$0.0005,000,000-31/12/2024\$0.0005,000,000-14/12/2025\$0.000-2,600,00028/11/2025\$0.000-2,000,00014/12/2025\$0.000-1,300,00028/11/2025\$0.000-1,300,00028/11/2025\$0.000-1,000,000	Expiry dateExercise pricethe start of the yearGrantedExercised31/12/2023\$0.0005,000,00031/12/2024\$0.0005,000,00014/12/2025\$0.000-2,600,000-28/11/2025\$0.000-2,000,000-14/12/2025\$0.000-1,300,000-28/11/2025\$0.000-1,000,000-	Exercise price the start of the year Granted Exercised forfeited/ other 31/12/2023 \$0.000 5,000,000 - - - - 31/12/2024 \$0.000 5,000,000 - - - - 31/12/2025 \$0.000 5,000,000 - - - - 31/12/2025 \$0.000 - 2,600,000 - - - 31/12/2025 \$0.000 - 2,000,000 - - - 14/12/2025 \$0.000 - 1,300,000 - - - 28/11/2025 \$0.000 - 1,000,000 - - -

The weighted average remaining contractual life of performance rights outstanding at the end of the financial year was 2 years (30 June 2023 2.21 years).



			No. of		
Tranches	Class of securities	Grant date	securities	Exercise price	Expiry date
Class A	Consultant performance rights	20/09/2023	2,000,000	Nil - convert to ordinary shares on achievement of non-market conditions.	-
Class B	Consultant performance rights	20/09/2023	2,500,000	Nil - convert to ordinary shares on achievement of non-market conditions.	-
Class D	Consultant performance rights	27/06/2024	1,000,000	Nil - convert to ordinary shares on achievement of non-market conditions.	-
Tranche A:1	KMP and employees' performance rights ¹	10/11/2023	3,000,000	Nil - convert to ordinary shares on achievement of market conditions.	4 years from date of issue
Tranche A:2	KMP and employees' performance rights ¹	10/11/2023	3,000,000	Nil - convert to ordinary shares on achievement of market conditions.	4 years from date of issue
Tranche A:3	KMP and employees' performance rights ¹	10/11/2023	3,000,000	Nil - convert to ordinary shares on achievement of market conditions.	4 years from date of issue
Dranche A:4	KMP and employees' performance rights ¹	10/11/2023	3,000,000	Nil - convert to ordinary shares on achievement of market conditions.	4 years from date of issue
Granche B:1	Employees' performance rights	10/11/2023	400,000	Nil - convert to ordinary shares subject to employment conditions.	4 years from date of issue
Tranche B:2	Employees' performance rights	10/11/2023	400,000	Nil - convert to ordinary shares subject to employment conditions.	4 years from date of issue
Granche B:3	Employees' performance rights	10/11/2023	800,000	Nil - convert to ordinary shares subject to employment conditions.	4 years from date of issue
С С С	Employee's performance rights	21/02/2024	188,877	Nil - convert to ordinary shares on achievement of performance targets and achievement of 30-day VWAP.	4 years from date of issue

¹ 900,000 Tranche A:1

l

900,000 Tranche A:2

900,000 Tranche A:3

900,000 Tranche A:4

A total of 3.6 million performance rights were issued on 27 June 2024 as these were subject to shareholders' approval.



Class of securities	Performance rights conditions
Class A	Milestone A: In the event of signed binding unconditional contract for the 1st paid pilot/contract (minimum annual contract value of USD\$250,000) with any USA based hospital within 12 months of engagement of the consultant.
	Milestone C: In the event of signed binding unconditional contract with a minimum of USD\$350,000 annual contract with a National Healthcare Organisation (such as the HCA), that has more than 7 clinics spread over more than 1 State of United States of America, all class A will vest immediately and immediately convert on one-for one basis into 2 million shares.
Class B	Milestone B: Subject to Milestone A above, 500,000 Class B will vest and immediately convert on a one-for one basis into 500,000 shares, with such milestone being capable of met multiple times (up to five) upon further and additional contracts being entered by the Company in satisfaction of this milestone up to an aggregate of 2,500,000 Class B performance rights vesting in accordance with these terms.
e on	Milestone C: In the event of signed binding unconditional contract with a minimum of USD\$350,000 annual contract with a National Healthcare Organisation (such as the HCA), that has more than 7 clinics spread over more than 1 State of United States of America, the remaining of 2,500,000 Class B will vest immediately and immediately convert on one-for one basis into 2.5 million shares.
Class D	The Management has assessed the probability of the Class A milestones being as 35% and 0% for Class B. Subject to the payment of the subscription amount pursuant to the Marin & Son subscription Agreement, 1,000,000 Class D Performance Rights will (to the extent not vested already) vest and immediately convert on a one-for-one basis into 1,000,000 shares in the event of a signed binding unconditional contract (minimum 18-months contract value of US\$1,000,000) with a managed service organisation.
Tranche A:1	The Management has assessed the probability of the Class D milestone being 40%. The SHG share price achieving a Volume Weighted Average Price (VWAP) of \$0.10 over any 15 consecutive
pere	days prior to expiry and continuous service until at least 30 June 2024. Tranche A - one quarter VWAP \$0.10 PR's - As at the half-year reporting date 31 Dec 2023 the VWAP milestone for \$0.10 PR's hadn't been met and therefore the vesting period should be up to 10 Nov 2027.
Tranche A:2	The SHG share price achieving a VWAP of \$0.15 over any 15 consecutive days prior to expiry and continuous service until at least 30 June 2024. The SHG share price achieving a VWAP of \$0.20 over any 15 consecutive days prior to expiry and continuous
Tranche A:4	service until at least 30 June 2024. The SHG share price achieving a VWAP of \$0.25 over any 15 consecutive days prior to expiry and continuous service until at least 30 June 2024.
Tranche B Cameron Bleech	 The Management has assessed the probability of the Class A milestones being as 35% and 0% for Class B. The SHG share calculated using a 30-day VWAP up to the 16th of January 2023, issued by the Company, and vesting on: continuous employment 6 months after the signing of this contract. upon achievement of the Performance Target. No escrow provisions will apply on any shares issued as a result of the issue of shares on the conversion of vested performance rights.



For the performance rights granted during the current financial year, the valuation model inputs used to determine the fair value at the grant date, are as follows:

				Share price at grant	Exercise	Expected volatility	Risk-free interest rate	VWAP	
Tranches	Methodology	Grant date	Expiry date	date	price	%	%	Hurdle	Fair value
A1	Monte-Carlo	10/11/2023	10/11/2027	\$0.041	\$0	100.27%	4.21%	\$0.10	\$0.036
A2	Monte-Carlo	10/11/2023	10/11/2027	\$0.041	\$0	100.27%	4.21%	\$0.15	\$0.033
A3	Monte-Carlo	10/11/2023	10/11/2027	\$0.041	\$0	100.27%	4.21%	\$0.20	\$0.031
A4	Monte-Carlo	10/11/2023	10/11/2027	\$0.041	\$0	100.27%	4.21%	\$0.25	\$0.029

For Class A and Class B, the fair value of the performance rights was valued at \$0.038 share price at the date of offer being 20 September 2023 and for Class C, the fair value was valued at \$0.099 share price at the date of shareholders' approval.

For Tranche B, the fair value of the performance rights was valued at \$0.041 share price at the date 10 November 2023 being the date of shareholder approval.

Accounting policy for share-based payments

Upquity-settled and cash-settled share-based compensation benefits are provided to employees.

Equity-settled transactions are awards of shares, or options over shares, that are provided to employees in exchange for the rendering of services. Cash-settled transactions are awards of cash for the exchange of services, where the amount of cash is determined by reference to the share price.

The cost of equity-settled transactions is measured at fair value on grant date. Fair value is independently determined using either the Monte-Carlo or Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of Gilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that do not determine whether the Group receives the Givervices that entitle the employees to receive payment. No account is taken of any other vesting conditions.

The cost of equity-settled transactions is recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of wards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods.

The cost of cash-settled transactions is initially, and at each reporting date until vested, determined by applying either the Binomial or Black-Scholes option pricing model, taking into consideration the terms and conditions on which the award was granted. The cumulative charge to profit or loss until settlement of the liability is calculated as follows:

- during the vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period.
- from the end of the vesting period until settlement of the award, the liability is the full fair value of the liability at the reporting date.

All changes in the liability are recognised in profit or loss. The ultimate cost of cash-settled transactions is the cash paid to settle the liability.

Market conditions are taken into consideration in determining fair value. Therefore, any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied.

If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification.



If the non-vesting condition is within the control of the Group or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the Group or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited.

If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification.

Note 12. Income tax

	30 June 2024 \$	30 June 2023 \$
Income tax expense		
Current tax	-	-
Deferred tax - origination and reversal of temporary differences	-	-
0		
Aggregate income tax expense	-	-
Numerical reconciliation of income tax expense and tax at the statutory rate		
Loss before income tax expense from continuing operations	(2,878,446)	(4,972,868)
Loss before income tax expense from discontinued operations	(2,046,258)	(417,450)
	(4,924,704)	(5,390,318)
	(4.224.476)	(4.2.47.500)
Tax at the statutory tax rate of 25% (2023: 25%)	(1,231,176)	(1,347,580)
• Tay affect amounts which are not deductible //tayable) in calculating tayable income:		
Var effect amounts which are not deductible/(taxable) in calculating taxable income: Non-allowable items	497,274	401,379
Revenue losses and other deferred tax balances not recognised	979,357	1,051,808
	575,557	1,051,808
	245,455	105,607
Less tax effect of:	2-13,-133	105,007
R&D tax incentive	(244,315)	(103,555)
Other non-assessable income	(1,140)	(2,052)
Income tax expense	-	-



Note 12. Income tax (continued)

	30 June 2024 \$	30 June 2023 \$
Deferred tax assets/liabilities not recognised at 25% (30 June 2023: 25%)		
Deferred tax assets not recognised comprises temporary differences attributable to:		
Leases	25,856	33,725
Provision and accruals	122,306	1,167,347
Plant and equipment	78,141	130,980
Transaction costs arising on shares issued	100,623	117,193
Other	26,029	71,296
Revenue losses	2,314,222	2,013,690
Deferred tax liabilities not recognised comprises temporary differences attributable to:		
> Prepayments	(336)	-
Plant and equipment	(35,760)	-
Plant and equipment under lease	(23,024)	-
Accrued interest	(833)	
Non-recognition of deferred tax liabilities/losses	2,607,224	3,534,231

The above potential tax benefit, which excludes tax losses, for deductible temporary differences has not been recognised in the statement of financial position as the recovery of this benefit is uncertain.

a	30 June 2024 30 June 20 \$\$\$
10	
Provision for income tax	<u> </u>
Accounting policy for income tax	
The income tax expense or benefit for the period is the tax payable on that period	
The income tax expense or benefit for the period is the tax payable on that period the tax payable on that period tax expense or benefit for the changes in deferred tax assets and liable tax between the changes in deferred tax assets and liable tax between the changes in deferred tax assets and liable tax between tax	
The income tax expense or benefit for the period is the tax payable on that period	
The income tax expense or benefit for the period is the tax payable on that period rate for each jurisdiction, adjusted by the changes in deferred tax assets and liable losses and the adjustment recognised for prior periods, where applicable.	ilities attributable to temporary differences, unused
The income tax expense or benefit for the period is the tax payable on that period rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabil losses and the adjustment recognised for prior periods, where applicable. Deferred tax assets and liabilities are recognised for temporary differences at the	ilities attributable to temporary differences, unused te tax rates expected to be applied when the assets
The income tax expense or benefit for the period is the tax payable on that period rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities losses and the adjustment recognised for prior periods, where applicable. Deferred tax assets and liabilities are recognised for temporary differences at th recovered or liabilities are settled, based on those tax rates that are enacted or s	ilities attributable to temporary differences, unused the tax rates expected to be applied when the assets substantively enacted, except for:
The income tax expense or benefit for the period is the tax payable on that period rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabil losses and the adjustment recognised for prior periods, where applicable. Deferred tax assets and liabilities are recognised for temporary differences at the recovered or liabilities are settled, based on those tax rates that are enacted or s When the deferred income tax asset or liability arises from the initial recognised for temporary differences at the settled.	ilities attributable to temporary differences, unused te tax rates expected to be applied when the assets substantively enacted, except for: nition of goodwill or an asset or liability in a transact
The income tax expense or benefit for the period is the tax payable on that period rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities losses and the adjustment recognised for prior periods, where applicable. Deferred tax assets and liabilities are recognised for temporary differences at the recovered or liabilities are settled, based on those tax rates that are enacted or s	ilities attributable to temporary differences, unused the tax rates expected to be applied when the assets substantively enacted, except for: nition of goodwill or an asset or liability in a transact affects neither the accounting nor taxable profits; o

- the reversal can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future.

Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

The carrying amount of recognised and unrecognised deferred tax assets are reviewed at each reporting date. Deferred tax assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable that there are future taxable profits available to recover the asset.

Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously.



Note 13. Cash and cash equivalents

	30 June 2024 \$	30 June 2023 \$
Current assets		
Cash at bank	453,360	691,513
Cash on deposit	1,000,000	-
	1,453,360	691,513
	1,433,300	051,515
Reconciliation to cash and cash equivalents at the end of the financial year The above figures are reconciled to cash and cash equivalents at the end of the financial year as shown in the statement of cash flows as follows:		
Balances as above	1,453,360	691,513
Cash and cash equivalents - classified as held for sale (note 17)	1,882	
Balance as per statement of cash flows	1,455,242	691,513

Counting policy for cash and cash equivalents

Gash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.



Note 14. Cash flow information

Reconciliation of loss after income tax to net cash used in operating activities

	30 June 2024 \$	30 June 2023 \$
Loss after income tax expense for the year	(4,924,704)	(5,390,318)
Adjustments for:		
Depreciation and amortisation	507,258	389,146
Impairment of investments	980,236	164,825
Write off of stocks	33,238	-
Share of loss - joint ventures	-	8,205
Share-based payments	1,285,081	1,267,114
Foreign exchange differences	(3,591)	-
Unwinding of the convertible note finance income	(302,174)	-
CImpact of AASB 16 Leases	12,221	36,987
Impact of divestment of Joint venture arrangements	7,120	-
Non-cash payments for services	-	57,600
Gapital allowance on receivables	17,675	-
Finance costs in relation to convertible notes	31,123	408,694
Wh terest and other finance costs	139,540	60,516
Change in operating assets and liabilities:		
Increase in trade and other receivables	(4,435)	(101,763)
Increase in inventories	(181,372)	-
Decrease in prepayments Increase/(decrease) in trade and other payables Decrease in contract liabilities Increase in other provisions	4,734	-
Increase/(decrease) in trade and other payables	(60,351)	695,852
Decrease in contract liabilities	(2,103)	-
Increase in other provisions	20,215	473
Det cash used in operating activities	(2,440,289)	(2,402,669)
Non-cash investing and financing activities		
Ū L	30 June 2024 \$	30 June 2023 \$
Additions to the right-of-use assets	-	139,538
Shares issued under employee share plan	1,285,081	1,267,114
Shares issued/(adjusted) in relation to business combinations	(247,500)	825,000
	1,037,581	2,231,652



Note 15. Trade and other receivables

	30 June 2024 \$	30 June 2023 \$
Current assets		
Trade receivables	3,412	6,326
Other receivables	27	16,500
Interest receivable	3,331	-
BAS receivable	55,875	53,360
	62,645	76,186

Accounting policy for trade and other receivables

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for settlement within 30 days.

The Group has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue.

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

Note 16. Right-of-use assets

	30 June 2024 \$	30 June 2023 \$
Non-current assets		
Cand and buildings - right-of-use	177,703	304,400
Land and buildings - right-of-use	(177,703)	(175,722)
	<u> </u>	128,678

During the year, the Group leases land and buildings for its offices and warehouses under agreements of between 5 to 7 years with, in some cases, options to extend. The leases have various escalation clauses. On renewal, the terms of the leases are renegotiated. The Group also leases plant and equipment under agreements of 3 years.

However, the leases have now classified as liabilities held for sale in the financial position as at 30 June 2024.

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

	\$
Balance at 1 July 2022	73,902
Additions through business combinations (note 29)	126,696
Depreciation expense	(71,920)
Balance at 30 June 2023	128,678
Classified as held for sale (note 17)	(92,094)
Depreciation expense	(36,584)
Balance at 30 June 2024	-

Singular Health Group Limited and its controlled entities Notes to the consolidated financial statements 30 June 2024



Note 16. Right-of-use assets (continued)

Accounting policy for right-of-use assets

A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the Group expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

The Group has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred.

Note 17. Assets of disposal groups classified as held for sale

The following assets were reclassified as held for sale in relation to the discontinued operation at 30 June 2024:

•
-
-
-
-
-
-
-

Accounting policy for assets of disposal groups held for sale

Non-current assets and assets of disposal groups are classified as held for sale if their carrying amount will be recovered principally through a sale transaction rather than through continued use. They are measured at the lower of their carrying amount and fair value ess costs of disposal. For non-current assets or assets of disposal groups to be classified as held for sale, they must be available for immediate sale in their present condition and their sale must be highly probable.

An impairment loss is recognised for any initial or subsequent write down of the non-current assets and assets of disposal groups to fair value less costs of disposal. A gain is recognised for any subsequent increases in fair value less costs of disposal of a non-current assets and assets of disposal groups, but not in excess of any cumulative impairment loss previously recognised.

Non-current assets are not depreciated or amortised while they are classified as held for sale. Interest and other expenses attributable to the liabilities of assets held for sale continue to be recognised.

Non-current assets classified as held for sale and the assets of disposal groups classified as held for sale are presented separately on the face of the statement of financial position, in current assets. The liabilities of disposal groups classified as held for sale are presented separately on the face of the statement of financial position, in current liabilities.



Note 18. Investments accounted for using the equity method

	30 June 2024 \$	30 June 2023 \$
Non-current assets Investment in associate - Australian Additive Engineering Pty Ltd		70,000

Interests in associates

Interests in associates are accounted for using the equity method of accounting. Information relating to associates that are material to the Group are set out below:

		Ownershi	p interest
	Principal place of business /	30 June 2024	30 June 2023
Name	Country of incorporation	%	%
Australian Additive Engineering Pty Ltd	Australia	-	25.00%
Puring the year, the Company finalised an agree Engineering Pty Ltd in consideration of \$70,000.	ement to dispose of its 25% shareholding in ${ m I}$	Melbourne-based Au	stralian Additive
B ummarised financial information			
n		30 June 2024	30 June 2023
		\$	\$
Cummarised statement of financial position			
Current assets		-	274,181
Non-current assets		-	292,649
0			
V otal assets		-	566,830
Qurrent liabilities		_	117,647
			117,047
Total liabilities		-	117,647
Onet assets		-	449,183
	,		
Summarised statement of profit or loss and other c Revenue	omprenensive income		1,158,959
Expenses		-	(1,285,155)
Loss before income tax		-	(126,196)
Other comprehensive income		-	38,622
Total comprehensive income			(87,574)
Reconciliation of the Group's carrying amount			
Opening carrying amount		70,000	243,030
Share of loss after income tax		-	(8,205)
Impairment expense		-	(164,825)
Disposal of associate		(70,000)	
Closing carrying amount			70 000
CIOSING CALLYING ANDUNIL		-	70,000

Note 19. Property, plant and equipment



	30 June 2024 \$	30 June 2023 \$
Non-current assets		
Leasehold improvements - at cost	31,525	22,488
Less: Accumulated depreciation	(5,374)	(86)
	26,151	22,402
Plant and equipment - at cost		793,025
Less: Accumulated depreciation	-	(107,534)
		685,491
Computer equipment - at cost	45,997	45,994
Sess: Accumulated depreciation	(36,496)	(24,966)
	9,501	21,028
office equipment - at cost	47,898	47,898
Less: Accumulated depreciation	(45,808)	(36,484)
\odot	2,090	11,414
S	37,742	740,335

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

UO	Office equipment	3D printers	Computer equipment	Improvements	Total
й.	\$	\$	\$	\$	\$
Balance at 1 July 2022	26,650	- 180,300	31,455	-	58,105 180,300
Additions through business combinations (note 29)	-	612,725	-	22,488	635,213
Depreciation expense	(15,237)	(107,534)	(10,426)	(86)	(133,283)
Balance at 30 June 2023	11,413	685,491	21,029	22,402	740,335
Additions	-	6,076	6,545	60,953	73,574
Classified as held for sale (note 17)	-	(204,404)	(5,991)	(42,795)	(253,190)
Impairment of assets	-	(220,660)	-	-	(220,660)
Depreciation expense	(9,323)	(266,503)	(12,082)	(14,409)	(302,317)
Balance at 30 June 2024	2,090		9,501	26,151	37,742

Accounting policy for property, plant and equipment

Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Depreciation is calculated on a straight-line basis to write off the net cost of each item of property, plant and equipment (excluding land) over their expected useful lives as follows:

Buildings	40 years
Leasehold improvements	5 years*
Plant and equipment	3-7 years

* leasehold improvements useful life revised from 3-10 years to 5 years over the unexpired period of the lease.



Note 19. Property, plant and equipment (continued)

The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date.

Leasehold improvements are depreciated over the unexpired period of the lease or the estimated useful life of the assets, whichever is shorter.

An item of property, plant and equipment is derecognised upon disposal or when there is no future economic benefit to the Group. Gains and losses between the carrying amount and the disposal proceeds are taken to profit or loss.

Note 20. Intangibles

	30 June 2024 \$	30 June 2023 \$
Non-current assets		
Goodwill - at cost	-	776,033
ntellectual property - at cost	737,790	737,790
Less: Accumulated amortisation	(624,091)	(467,276)
Φ	113,699	270,514
N. S.	113,699	1,046,547

<u>R</u>econciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

CO S	Goodwill \$	Intellectual property \$	Total \$
Balance at 1 July 2022 Additions through business combinations (note 29) Amortisation expense	- 776,033 -	454,456 - (183,942)	454,456 776,033 (183,942)
Balance at 30 June 2023 Bair value adjustments through business combination (note 29) Impairment of assets Amortisation expense	776,033 (91,693) (684,340)	270,514 - - (156,815)	1,046,547 (91,693) (684,340) (156,815)
Balance at 30 June 2024	<u> </u>	113,699	113,699

Accounting policy for intangible assets

Intangible assets acquired as part of a business combination, other than goodwill, are initially measured at their fair value at the date of the acquisition. Intangible assets acquired separately are initially recognised at cost. Indefinite life intangible assets are not amortised and are subsequently measured at cost less any impairment. Finite life intangible assets are subsequently measured at cost less amortisation and any impairment. The gains or losses recognised in profit or loss arising from the derecognition of intangible assets are measured as the difference between net disposal proceeds and the carrying amount of the intangible asset. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method or period.

Goodwill

Goodwill arises on the acquisition of a business as detailed in **note 29**. Goodwill is not amortised. Instead, goodwill is tested annually for impairment, or more frequently if events or changes in circumstances indicate that it might be impaired, and is carried at cost less accumulated impairment losses. Impairment losses on goodwill are taken to profit or loss and are not subsequently reversed.



Note 20. Intangibles (continued)

Intellectual property

Significant costs associated with intellectual property are deferred and amortised on a straight-line basis over the period of their expected benefit, being their finite life of 10 years.

Note 21. Trade and other payables

	30 June 2024 \$	30 June 2023 \$
Current liabilities		
Trade payables	50,689	161,003
Other payables	264,988_	172,389
>	315,677	333,392

Refer to **note 27** for further information on financial instruments.

Accounting policy for trade and other payables

These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

Note 22. Borrowings

	30 June 2024 \$	30 June 2023 \$
0		
Gurrent liabilities		
Coan - R&D finance	191,486	419,236
Diterest payable on R&D loan	13,352	15,833
Loan - Tremolat Pty Ltd	-	560,000
🖸 🖸 🗠 🕐 🕐 🕐 🕐 🖉	-	1,281
Loan - Premium funding	13,615	-
Convertible notes payable	-	1,208,694
Gire purchase	-	30,956
	218,453	2,236,000
Non-current liabilities		
Hire purchase		139,611
	218,453	2,375,611

Refer to **note 27** for further information on financial instruments.

Total secured liabilities

The total secured liabilities are as follows:

Lender	Radium Capital
Principal amount:	\$420,000
Interest:	16% per annum
Term:	30 November 2023
Security:	Company's future right, title and interest in the refund which Company entitled.
Repayment:	Repaid both principal and interest during the financial year.



Note 22. Borrowings (continued)

Lender	Radium Capital
Principal amount:	\$192,250
Interest:	15% per annum
Term:	30 November 2024
Security:	Company's future right, title and interest in the refund which Company entitled.
Repayment:	Repaid both principal and interest on due date.
Lender	Tremolat Pty Ltd
Principal amount:	\$560,000
Interest:	12% per annum, paid monthly
Term:	12 months (13 January 2023 to 13 January 2024) extended to 13 April 2024
Security:	Secured against 3D printing plant and equipment
Repayment:	Repaid both principal and interest during the financial year.
Lender	Brightstar Corporation Pty Ltd
	\$500,000
Principal amount:	
Conterest:	15% per annum, paid monthly in arrears
Term:	6 months (16 October 2023 to 16 April 2024)
Security:	Secured against any present or future property, undertaking assets or revenues of the borrower.
Repayment:	Repaid both principal and interest during the financial year.
Lender	HP Enterprise Financial Services
Principal amount:	\$180,300
Interest:	4.76% per annum, paid monthly in arrears
(Term:	60 months
Security:	Secured against vapor fuse plant and equipment.
Bepayment:	Monthly repayment of principal and interest.
Convertible notes payable	
	<i>-</i> 30 June 2024 30 June 2023
	50 June 2024 30 June 2023

\bigcirc	\$	\$
Opening balance	1,208,694	-
Legayment of convertible notes and interest	(929,862)	-
Convertible notes issued	-	800,000
Capitalised interest (at 15% per annum ¹)	23,341	106,520
Finance (income)/cost ²	(302,173)	302,174
	<u>-</u>	1,208,694

¹ The capitalised interest represents the interest payable on the convertible notes. It is calculated based on 15% per annum of the face value of the convertible notes on issue, from issue date to 30 June 2023 and the maturity date of 15 August 2023. The interest expense of \$129,862 was redeemed at maturity date (15 August 2023).

² The finance cost of \$302,174 was recognised the discount value up to the maturity date of the convertible notes. The finance income of \$302,174 related to de-recognition of the convertible note which was fully repaid rather than converted into securities.

Settlement of convertible notes

Where notes are settled by issue of shares, the related financial liabilities are derecognised at their carrying value with the corresponding increase to share capital. Any costs incurred are recognised in profit or loss.

Where notes are settled by payment of cash the related financial liabilities are derecognised at their carrying value and the difference between total cash consideration paid and the carrying value of the financial liabilities derecognised is recognised in profit or loss.

Singular Health Group Limited and its controlled entities Notes to the consolidated financial statements 30 June 2024



Note 22. Borrowings (continued)

Accounting policy for borrowings

Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction costs. They are subsequently measured at amortised cost using the effective interest method.

The component of the convertible notes that exhibits characteristics of a liability is recognised as a liability in the statement of financial position, net of transaction costs.

On the issue of the convertible notes the fair value of the liability component is determined using a market rate for an equivalent nonconvertible bond and this amount is carried as a non-current liability on the amortised cost basis until extinguished on conversion or redemption. The increase in the liability due to the passage of time is recognised as a finance cost. The remainder of the proceeds are allocated to the conversion option that is recognised and included in shareholders equity as a convertible note reserve, net of transaction costs. The carrying amount of the conversion option is not remeasured in the subsequent years. The corresponding interest on convertible notes is expensed to profit or loss.

Note 23. Lease liabilities

	30 June 2024 \$	30 June 2023 \$
Qurrent liabilities		
Cease liability		42,086
Non-current liabilities		
Gease liability	-	92,815
	-	134,901
		134,501
Reconciliation of lease liabilities		
Opening balance	134,901	84,541
Addition	-	126,123
Genterest	25,636	8,986
Payment	(57,113)	(84,749)
Transfer to liabilities held for sale 24	(103,424)	
0	-	134,901

Refer to **note 27** for further information on financial instruments.

Accounting policy for lease liabilities

A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Group's incremental borrowing rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in the period in which they are incurred.

Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an adjustment is made to the corresponding right-of use asset, or to profit or loss if the carrying amount of the right-of-use asset is fully written down.



Note 24. Liabilities directly associated with assets classified as held for sale

The following liabilities were reclassified as held for sale in relation to the discontinued operation at 30 June 2024:

	30 June 2024 \$	30 June 2023 \$
Current liabilities		
Trade payables	1,950	-
Other payables	15,944	-
Hire purchase	139,689	-
Lease liabilities	103,424	
	261,007	

Note 25. Issued capital

UO	30 June 2024	30 June 2023	30 June 2024	30 June 2023
O	Shares	Shares	\$	\$
Ordinary shares - fully paid	195,603,055	134,037,538	17,937,346	12,735,077
Sapital raising cost			(1,506,569)	(757,513)
D	195,603,055	134,037,538	16,430,777	11,977,564

Movements in ordinary share capital

	_			
Details	Date	Shares	Issue price	<u></u> \$
0				
Balance	1-Jul-22	102,798,867		9,526,669
<u>Š</u> hare purchase plan	22-Dec-22	5,147,762	\$0.115	592,000
Acquisition of Global 3D	23-Jan-23	5,500,000	\$0.150	825,000
Placement shares - Tranche 1	5-Apr-23	7,699,997	\$0.055	423,500
Placement shares - Tranche 2	21-Jun-23	11,390,912	\$0.055	626,500
Shares issued to employee and consultant	26-Jun-23	300,000	\$0.048	14,400
hares issued to Grange Consulting Group	26-Jun-23	1,200,000	\$0.048	57,600
Capital raising cost		-	\$0.000	(88,105)
			_	
Balance	30-Jun-23	134,037,538		11,977,564
Shares issued under strategic placement	10-Nov-23	7,272,727	\$0.055	400,000
Fair value adjustment on business combination note 29	31-Dec-23	-	\$0.000	(247,500)
Placement shares to CG1 Ventures	9-Feb-24	15,454,545	\$0.055	850,000
Placement shares	21-Feb-24	37,483,101	\$0.110	4,123,141
Shares issued from exercise of options	21-Feb-24	766,267	\$0.100	76,627
Shares issued to employees from conversion of				
performance rights	21-Feb-24	338,877	\$0.000	-
Shares issued to employees from conversion of				
performance rights	21-May-24	250,000	\$0.000	-
Capital raising cost ¹	27-Jun-24	-	·	(467,702)
Capital raising cost		-		(281,353)
			-	<u> </u>
Balance	30-Jun-24	195,603,055		16,430,777
		,	=	

¹ 8.5 million options were approved by the shareholders on 27 June 2024 and were issued subsequent to 30 June 2024. Capital raising cost was recognised during the financial year as the mutual agreements were signed.



Note 25. Issued capital (continued)

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share buy-back

ഗ

Π

There is no current on-market share buy-back.

Capital risk management

The Group's objectives when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital.

Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total position, plus net debt. Net debt is calculated as total position, plus net debt. Net debt is calculated as total position, plus net debt. Net debt is calculated as total position, plus net debt. Net debt is calculated as total position, plus net debt. Net debt is calculated as total position, plus net debt. Net debt is calculated as total position, plus net debt. Net debt is calculated as total

In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return capital shareholders, issue new shares or sell assets to reduce debt.

The Group would look to raise capital when an opportunity to invest in a business or company was seen as value adding relative to the current Company's share price at the time of the investment. The Group is not actively pursuing additional investments in the short term as it continues to integrate and grow its existing businesses in order to maximise synergies.

The Group is subject to certain financing arrangements covenants and meeting these is given priority in all capital risk management decisions. There have been no events of default on the financing arrangements during the financial year.

The capital risk management policy remains unchanged from the 30 June 2023 Annual Report.

Counting policy for issued capital

Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

Note 26. Reserves

	30 June 2024 \$	30 June 2023 \$
Foreign currency translation reserve	2,393	(4,653)
Share-based payments reserve	4,123,346	3,206,405
Performance rights reserve	1,689,249	1,020,082
Share-based payments reserve (yet to issued)	99,000	
	5,913,988	4,221,834



Note 26. Reserves (continued)

Movements in reserves

Movements in each class of reserve during the current and previous financial year are set out below:

Reconciliation of movement in performance rights

Reconcination of movement in performance rights			
	Issued	No. of	
	Date	performance rights	\$
Balance at 1 July 2022		10,000,000	987,111
Performance rights granted	28-Nov-22	3,900,000	235,190
Performance rights granted	14 Dec-22	3,000,000	81,489
Vesting of employee performance rights		-	716,292
Change in valuation of Class A performance rights		-	(1,000,000)
Balance at 30 June 2023		16,900,000	1,020,082
>			
Performance rights granted to consultant (agreed date: 20-Sep-23)	10-Nov-23	4,500,000	53,221
Performance rights granted to Directors and employees	10-Nov-23	12,000,000	72,668
Rerformance rights granted to employees	10-Nov-23	1,600,000	46,840
Performance rights (expired: 31 Dec 2023)		(5,000,000)	-
Rerformance rights granted to employee	21-Feb-24	188,877	20,776
Conversion of performance rights to ordinary shares	21-Feb-24	(588,877)	(37,176)
Sesting of employee performance rights	-	-	512,836
Balance at 30 June 2024	_	29,600,000	1,689,247

Singular Health Group Limited and its controlled entities Notes to the consolidated financial statements 30 June 2024



Note 26. Reserves (continued)

Reconciliation of movement in options

	Issued	No. of	
·	Date	options	\$
Balance at 1 July 2022		22,820,000	2,389,179
Options issued to referrers in respect of convertible notes	3-Aug-22	800,000	24,444
Options issued to consultants in respect of advisory work	28-Nov-22	5,000,000	295,000
Free attaching options issued as part of capital raise		15,240,918	, _
Options issued to consultants in respect of promotional and	16-Jun-23	, ,	
associated activities		500,000	8,983
Options issued to lead manager in respect of capital raise	16-Jun-23	3,500,000	62,883
Free attaching options issued to Grange Consulting Group	16-Jun-23	1,200,000	-
Free attaching transaction options to Global 3D (Grant date: 25-Jan-	16-Jun-23		
23)		1,720,000	-
Vesting expense - Options issued to Directors as incentive-based			
Cremuneration in previous period		-	595,246
esting expense - Options issued to KMP and consultant as incentive-			,
based remuneration in previous period		-	238,188
Lapsed options		(40,000)	(5,000)
Expired options		-	(402,518)
Galance at 30 June 2023		50,740,918	3,206,405
		<u> </u>	<u> </u>
Valuation on options issued to Global 3D for business combination			
(note 29)		-	90,976
Options granted to KMP and consultant (Grant date: 10-Nov-23)	8-Dec-23	15,500,000	381,332
Free attaching options issued to Brightstar Corporation Pty Ltd (Grant	14-Aug-23	, ,	,
C date: 16-Jun-23)	U	3,636,363	-
Exercised of options (Grant date: 16-Jun-23)	21-Feb-24	(766,267)	-
Pree attaching options in respect of capital raise	9-Feb-24	7,727,272	-
Deptions granted to broker in respect of capital raise (Grant date: 27-	8-Feb-24	, ,	
Qun-24) ¹		-	467,702
Options issued to employees (Grant date: 10-Nov-23)	27-Jun-24	4,000,000	98,408
Expired of options (Expired: 10-Jan-24)		(1,000,000)	(121,477)
			<u> </u>
Balance at 30 June 2024		79,838,286	4,123,346

¹8.5 millions of options were issued on 25 July 2024, subsequent to financial year end. Capital raising cost was recognised during the year as both parties have mutually agreed on 8 February 2024 as per the mandate.

Share-based payment reserves (yet to be issued at 30 June 2024)

On 27 June 2024, the shareholders granted the following equities, and the equities were issued subsequent to 30 June 2024:

- 1,000,000 ordinary shares valued at \$0.099 to Nigel Brown as mutual agreement signed between the parties during the year. Sharebased payment of \$99,000 recognised during the year.

Accounting policy for reserves

Share-based payments reserve

The reserve is used to recognise the value of equity benefits provided to employees and Directors as part of their remuneration, and other parties as part of their compensation for services.

Foreign currency reserve

The reserve is used to recognise exchange differences arising from the translation of the financial statements of foreign operations to Australian dollars. It is also used to recognise gains and losses on hedges of the net investments in foreign operations.



Note 27. Financial instruments

Financial risk management objectives

The Group's activities expose it to a variety of financial risks: market risk (including foreign currency risk, price risk and interest rate risk), credit risk and liquidity risk. The Group's overall risk management program focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the financial performance of the Group. The Group does not use derivative financial instruments; however, the Group uses different methods to measure different types of risk to which it is exposed. These methods include sensitivity analysis in the case of interest rate, and other price risks and aging analysis for credit risk.

Risk management is carried out by Board of Directors ('the Board') with assistance from suitably qualified external and internal advisors. These policies include identification and analysis of the risk exposure of the Group and appropriate procedures, controls and risk limits. Finance identifies, evaluates within the Group's operating units. Finance reports to the Board on a quarterly basis and the Board provides written principles for overall risk management and further policies evolve commensurate with the evolution and growth of the Group.

Market risk

Foreign currency risk

The Group undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations.

The Group operated predominantly in Australia in the year ended 30 June 2024 and had minimal exposure to foreign exchange risk.

Price risk

The Group is not exposed to any significant price risk.

Interest rate risk

The Group's main interest rate risk arises from short-term borrowings and hold cash at bank with variable interest rates. Borrowings

Credit risk

Gredit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Group. The Group has a strict code of credit, including obtaining agency credit information, confirming references and setting appropriate credit Timits as a means of mitigating the risk of financial loss from defaults. The maximum exposure to credit risk at the reporting date to recognised financial assets is the carrying amount, net of any provisions for impairment of those assets, as disclosed in the statement of financial position and notes to the financial statements. The Group does not hold any collateral.

Generally, trade receivables are written off when there is no reasonable expectation of recovery. Indicators of this include the failure of a debtor to engage in a repayment plan, no active enforcement activity and a failure to make contractual payments for a period greater Lthan 1 year.

The credit quality of financial assets that are neither past due not impaired can be assessed by reference to external credit ratings:

	30 June 2024 \$	30 June 2023 \$
Cash and cash equivalents	1,453,360	691,513

Allowance for expected credit losses

The Group has recognised a discontinued loss of \$17,675 (30 June 2023: \$nil) in profit or loss in respect of the expected credit losses for the year ended 30 June 2024.

Liquidity risk

Vigilant liquidity risk management requires the Group to maintain sufficient liquid assets (mainly cash and cash equivalents) and available borrowing facilities to be able to pay debts as and when they become due and payable.

The Group manages liquidity risk by maintaining adequate cash reserves and available borrowing facilities by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities.



Note 27. Financial instruments (continued)

Remaining contractual maturities

Prudent liquidity risk management implies maintaining sufficient cash and marketable securities, the availability of funding through an adequate amount of committed credit facilities and the ability to close out market positions. The Group manages liquidity risk by continuously monitoring forecast and actual cash flows and matching the maturity profits of financial assets and liabilities. As at reporting date the Group had sufficient cash reserves to meet its requirements. The Group therefore had no credit standby facilities or arrangements for further funding in place.

The financial liabilities of the Group at reporting date were trade and other payables, borrowings, and lease liabilities incurred in the normal course of the business. Trade and other payables were non-interest bearing and were due within the normal 30-60 days terms of creditor payments. Borrowings have fixed terms of repayment and interest payable. The Group also has lease liabilities, which are payable over the term of the related lease agreements. The Group does not consider these liabilities to be material to the Group and have therefore not undertaken any further analysis of risk exposure.

The following tables detail the Group's remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the statement of financial position.

3 0 June 2024	Weighted average interest rate %	Less than 6 months \$	1 year or less \$	Between 1 and 2 years \$	Between 2 and 5 years \$	Over 5 years \$	Remaining contractual maturities \$
Non-derivatives							
Won-interest bearing							
Trade payables	-	50,689	-	-	-	-	50,689
Other payables	-	264,988	-	-	-	-	264,988
W terest-bearing - fixed rate							
Other loans	9.68%	218,453	-	-	-	-	218,453
Dotal non-derivatives		534,130	-	-	-	-	534,130
Õ							
	Weighted						Remaining
<u> </u>	average	Less than 6		Between 1	Between 2		contractual
0	interest rate	months	1 year or less	and 2 years	and 5 years	Over 5 years	maturities
30 June 2023	%	\$	\$	\$	\$	\$	\$
Non-derivatives							
Non-interest bearing							
Trade payables	-	161,003	-	-	-	-	161,003
Other payables	-	172,389	-	-	-	-	172,389
Interest-bearing - fixed rate							
Other loans	13.50%	2,220,167	15,833	139,611	-	-	2,375,611
		20.270	12.010	02.015			124 001
Lease liability	10.50%	29,270	12,816	92,815	-	-	134,901

The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above.

Fair value of financial instruments

Unless otherwise stated, the carrying amounts of financial instruments reflect their fair value.



Note 28. Fair value measurement

The carrying amounts of trade and other receivables and trade and other payables are assumed to approximate their fair values due to their short-term nature.

The fair value of financial liabilities is estimated by discounting the remaining contractual maturities at the current market interest rate that is available for similar financial liabilities.

Accounting policy for fair value measurement

When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market.

Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interests. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

Assets and liabilities measured at fair value are classified into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed at each reporting date and transfers between levels are determined based on a reassessment of the lowest level of input that is significant to the fair value measurement.

For recurring and non-recurring fair value measurements, external valuers may be used when internal expertise is either not available or when the valuation is deemed to be significant. External valuers are selected based on market knowledge and reputation. Where there is a significant change in fair value of an asset or liability from one period to another, an analysis is undertaken, which includes a verification of the major inputs applied in the latest valuation and a comparison, where applicable, with external sources of data.

Note 29. Business combinations

Con 25 January 2023, Singular 3DP Pty Ltd, a subsidiary of Singular Health Group Limited, acquired certain 3D printing assets, related plant and equipment, intellectual property and existing medical focused 3D printing business of Global 3DP Pty Limited. Global 3D is a West-Australian company providing advanced 3D printing services from an established ISO-9001 accredited facility.

As discussed in **note 1** of 30 June 2023 annual report, business combinations are initially accounted for on a provisional basis. The fair value of assets acquired, liabilities and contingent liabilities assumed are initially estimated by the Group taking into consideration all or value of assets acquired, liabilities and contingent liabilities assumed are initially estimated by the Group taking into consideration all or value of the provision at the reporting date. Fair value adjustments on the finalisation of the business combination accounting are retrospective, where applicable, to the period the combination occurred and may have an impact on the assets and liabilities, depreciation and amortisation reported.

The values identified in relation to the acquisition are final as at 30 June 2024.



Note 29. Business combinations (continued)

Details of the acquisition are as follows:

	Provisional value	Fair value adjustment	Fair value
	30 June 2023 \$	\$	30 June 2024 \$
Other receivables (GST)	61,272	-	61,272
Plant and equipment	612,725	-	612,725
Right-of-use assets	126,696	-	126,696
Employee benefits	(12,305)	(3,556)	(15,861)
Lease liability	(126,696)	-	(126,696)
Net assets acquired	661,692	(3,556)	658,136
Goodwill	776,033	(91,693)	684,340
Cquisition-date fair value of the total consideration transferred	1,437,725	(95,249)	1,342,476
Representing:			
Cash paid or payable to vendor	(612,725)	(61,273)	(673,998)
Singular Health Group Limited shares issued to vendor	(825,000)	247,500	(577,500)
Singular Health Group Limited options issued to vendor	<u> </u>	(90,978)	(90,978)
Ø	(1,437,725)	95,249	(1,342,476)

Consideration transferred

Acquisition related costs of \$86,000 not included as part of the consideration for the acquisition but are included in transaction expense m profit or loss in this financial year.

Shares - at completion date, 5,500,000 SHG shares with a fair value of \$577,500 issue price of \$0.105 per share (share price at date of completion 25 January 2023).

2) Options - at completion date, 1,720,000 unlisted options exercise price of \$0.20 expiry in 3 years from date of completion valued at \$90,978 (refer below for valuation).

Grant date	Expiry date	Share price at grant date	Exercise price	Expected volatility %	Dividend yield %	Risk-free interest rate %	Fair value at grant date
25/01/2023	24/01/2026	\$0.10	\$0.20	100.00%	-	3.22%	\$0.053

3) Cash - \$673,998 to settle the financial liabilities of Global 3DP.

4) Earn-out shares - earn up to a further 900,000 fully paid ordinary shares (Earn-out shares) and 280,000 free unlisted options from 1st anniversary of completion of transaction. The earn out shares and options are triggered in the event Singular 3DP achieves gross revenue within the 12 months following completion of the transaction in excess of \$550,000 [subject to Singular 3DP also achieving an EBITDA margin equal to or greater than 10% on gross revenue during the same period.

Management of SHG has assessed that based on the accounts dated 30 June 2024, the earn- out conditions will not be satisfied.

5) Performance rights - at completion date, performance rights as per below table to be issued to Nigel Brown and Paul Cummings.



Note 29. Business combinations (continued)

Tranche	Class of securities	Grant date	No. of securities Exercise price Expiry date
Indiferie		diant date	
A1	KMP performance rights	25-Jan-2023	333,334 Nil - convert to ordinary shares on 2 years from date achievement of non-market of issue conditions
B1	KMP performance rights	25-Jan-2023	333,333 Nil - convert to ordinary shares on 2 years from date achievement of non-market of issue conditions
C1	KMP performance rights	25-Jan-2023	1,666,667 Nil - convert to ordinary shares on 2 years from date achievement of non-market of issue conditions
D1	KMP performance rights	25-Jan-2023	666,667 Nil - convert to ordinary shares on 2 years from date achievement of non-market of issue conditions
			3,000,001

Management of SHG has assessed that based on the accounts dated 30 June 2024, the performance rights will not be satisfied.

Accounting judgements, estimates and assumptions

The consideration transferred is the sum of the acquisition-date fair values of the assets transferred and equity instruments issued. All acquisition costs are expensed as incurred to profit or loss.

The following key estimates and judgements were required as part of the acquisition accounting for the 3D printing business:

Property, plant, and equipment - the valuation of these assets involved use of, amongst other factors, publicly available historical capital quit costs, industry benchmarks, current replacement costs, useful life assumptions, residual values to determine current asset conditions and utilisation.

Deferred tax liability - the recognition of deferred tax liabilities is directly associated with the determination of both initial accounting alues and the determination and allocation of tax bases on entry into the Group's tax consolidated group. The balance reflects the nondeductibility for tax purposes of the intangible assets.

Accounting policy for business combinations

The acquisition method of accounting is used to account for business combinations regardless of whether equity instruments or other assets are acquired.

The consideration transferred is the sum of the acquisition-date fair values of the assets transferred, equity instruments issued or liabilities incurred by the acquirer to former owners of the acquiree and the amount of any non-controlling interest in the acquiree. For each business combination, the non-controlling interest in the acquiree is measured at either fair value or at the proportionate share of the acquiree's identifiable net assets. All acquisition costs are expensed as incurred to profit or loss.

On the acquisition of a business, the Group assesses the financial assets acquired and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic conditions, the Group's operating or accounting policies and other pertinent conditions in existence at the acquisition-date.

Where the business combination is achieved in stages, the Group remeasures its previously held equity interest in the acquire at the acquisition-date fair value and the difference between the fair value and the previous carrying amount is recognised in profit or loss.

Contingent consideration to be transferred by the acquirer is recognised at the acquisition-date fair value. Subsequent changes in the fair value of the contingent consideration classified as an asset or liability is recognised in profit or loss. Contingent consideration classified as equity is not remeasured and its subsequent settlement is accounted for within equity.

Singular Health Group Limited and its controlled entities Notes to the consolidated financial statements 30 June 2024



Note 29. Business combinations (continued)

The difference between the acquisition-date fair value of assets acquired, liabilities assumed and any non-controlling interest in the acquiree and the fair value of the consideration transferred and the fair value of any pre-existing investment in the acquiree is recognised as goodwill. If the consideration transferred and the pre-existing fair value is less than the fair value of the identifiable net assets acquired, being a bargain purchase to the acquirer, the difference is recognised as a gain directly in profit or loss by the acquirer on the acquisition-date, but only after a reassessment of the identification and measurement of the net assets acquired, the non-controlling interest in the acquirer, if any, the consideration transferred and the acquirer's previously held equity interest in the acquirer.

Business combinations are initially accounted for on a provisional basis. The acquirer retrospectively adjusts the provisional amounts recognised and also recognises additional assets or liabilities during the measurement period, based on new information obtained about the facts and circumstances that existed at the acquisition-date. The measurement period ends on either the earlier of (i) 12 months from the date of the acquisition or (ii) when the acquirer receives all the information possible to determine fair value.

Note 30. Key management personnel disclosures

Directors			
The following persons were Directors of Singular Health Group	Limited during the financial year:		
H oward Digby	Non-Executive Chairman		
Denning Chong		tive Officer	
Andrew Just	Managing Director and Chief Executive Officer Non-Executive Director		
Andrew Just	Non-Executive Director		
Other key management personnel			
The following persons also had the authority and responsibility	for planning, directing and controlling the	ne major activitie	es of the Group,
directly or indirectly, during the financial year:			
James Hill	Chief Operating Officer		
Kyla Garic	Chief Financial Officer (from 13 November 2023)		
Martina Mariano	Chief Commercial Officer (from 9 February 2024)		
()			
C ompensation			
The aggregate compensation made to Directors and other mem	bers of key management personnel of t	he Group is set c	out below:
Õ			
		30 June 2024	30 June 2023
		\$	\$
0			
Short-term employee benefits		463,349	779,469
Post-employment benefits		64,062	49,750
Share-based payments		714,719	1,510,996
	_	1,242,130	2,340,215

Note 31. Related party transactions

Parent entity Singular Health Group Limited is the ultimate Australian parent entity.

Subsidiaries Interests in subsidiaries are set out in **note 34**.

Associates Interests in associates are set out in **note 18**.

Joint operations Interests in joint operations are set out in **note 35**.



Note 31. Related party transactions (continued)

Key management personnel

Disclosures relating to key management personnel are set out in note 30 and the remuneration report included in the Directors' report.

During the year, the following equities were granted to the following ex-KMP:

КМР	Designation	Nature of securities
Mr Paul Cummings ¹	Director of 3DP	3,000,001 performance rights
Mr Nigel Brown ²	Director of 3DP	1,000,000 ordinary shares
Ms Wendy Figueroa ³	Director of 3DP/ Financial Controller	400,000 performance rights

¹ The Management of SHG has assessed that based on the accounts dated 30 June 2024, the performance rights will not be satisfied. Mr. Cummings resigned 11 April 2024.

² Mr. Brown resigned 24 October 2023. Shares were yet to be issued as at 30 June 2024, however, share-based payment recognised as the deed of settlement was signed on 28 March 2024.

³Ms. Figuera resigned on 28 April 2024.

ransactions with related parties

Re-Energise Digital, a company associated with James Hill, received \$2,106 excluding GST in fees (30 June 2023: \$19,064) during the year for marketing services provided to the Company, with \$nil payable at 30 June 2024.

Grange Consulting Group Pty Ltd, of which Steven Wood is a Director, received \$86,400 excluding GST (30 June 2023: \$137,494) during the year for financial services, company secretarial work and corporate advisory services. These services are provided on normal commercial terms and at arm's length, with nil balance payable as at 30 June 2024.

Onyx Corporate Pty Ltd, of which Kyla Garic is a Director, received \$65,000 excluding GST (30 June 2023: \$nil) during the year for corporate financial services. These services are provided on normal commercial terms and at arm's length, with nil balance payable as 30 June 2024.

S Receivable from and payable to related parties

There were no trade receivables from or trade payables to related parties at the current and previous reporting date.

Loans to/from related parties

There were no loans to or from related parties at the current and previous reporting date.

derms and conditions

All transactions were made on normal commercial terms and conditions and at market rates.

Note 32. Commitments and contingent liabilities

There are no other contingent liabilities or commitments at 30 June 2024 and 30 June 2023.

Singular Health Group Limited and its controlled entities Notes to the consolidated financial statements 30 June 2024



Note 33. Parent entity information

Set out below is the supplementary information about the parent entity.

Statement of profit or loss and other comprehensive income

	30 June 2024 \$	30 June 2023 \$
Loss after income tax	(12,095,466)	(9,855,690)
Total comprehensive income	(12,095,466)	(9,855,690)
Statement of financial position		
	30 June 2024 \$	30 June 2023 \$
Gotal current assets	1,467,399	636,020
Total non-current assets	113,699	704,039
Potal assets		1,340,059
Total current liabilities	147,764	1,278,770
Lotal liabilities	147,764	1,278,770
Cequity Issued capital Foreign currency translation reserve Share-based payments reserve Performance rights reserve	16,430,777 (3,330) 4,123,346 1,689,249	11,977,564 - 3,206,405 1,018,917
O Share-based payments reserve (yet to issued)	99,000	-
Accumulated losses	(20,905,708)	(16,141,597)
T otal equity	1,433,334	61,289

Guarantees entered into by the parent entity in relation to the debts of its subsidiaries

The parent entity had no guarantees in relation to the debts of its subsidiaries as at 30 June 2024 and 30 June 2023.

Contingent liabilities

The parent entity had no contingent liabilities as at 30 June 2024 and 30 June 2023.

Capital commitments - Property, plant and equipment

The parent entity had no capital commitments for property, plant and equipment as at 30 June 2024 and 30 June 2023.

Material accounting policy information

The accounting policies of the parent entity are consistent with those of the Group, as disclosed in note 1, except for the following:

- Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity.
- Investments in associates are accounted for at cost, less any impairment, in the parent entity.
- Dividends received from subsidiaries are recognised as other income by the parent entity and its receipt may be an indicator of an impairment of the investment.



Note 34. Interests in subsidiaries

The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in **note 1**:

Name		Ownership interest			
	Principal place of business /	30 June 2024	30 June 2023		
	Country of incorporation %		%		
Singular Health Pty Ltd	Australia	100%	100%		
Singular Health Pte Ltd	Singapore	100%	100%		
Singular 3DP Pty Ltd	Australia	100%	100%		

Note 35. Interests in joint operations

The Group has recognised its share of jointly held assets, liabilities, revenues and expenses of joint operations. These have been incorporated in the financial statements under the appropriate classifications. Information relating to joint operations that are material to the Group are set out below:

0		Ownershi	p interest
Quame	Principal place of business / Country of incorporation	30 June 2024 %	30 June 2023 %
S		/0	
GeoVR Pty Ltd	Australia	-	50.00%
Singular International Medical Technology Ltd	Macau, China	50.00%	50.00%

Woint arrangement in GeoVR Pty Ltd

During the year, the Company divested the 50% interest in GeoVR Pty Ltd. The loan of \$2,200 provided was fully written off.

joint arrangement in Singular International Medical Technology Ltd

Singular Health Pte Ltd, a wholly owned subsidiary of Singular Health Group Limited, has a 50% interest in a joint operation called SH Medical Technology Ltd which was set up as a Joint Arrangement Company together with sophisticated individual investors to investigate arket potential for Scan to Surgery technology in the East Asian market. The principal place of business of the joint arrangement is in Macau. Singular International Medical Technology Ltd has had minimal activities since its establishment.

Accounting policy for interest in joint operations

joint operation is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the assets, and obligations for the liabilities, relating to the arrangement. The Group has recognised its share of jointly held assets, liabilities, revenues and expenses of joint operations. These have been incorporated in the financial statements under the appropriate classifications.



Note 36. Events after the reporting period

Date	Details
4 July 2024	The Company received the AUD\$1 million investment from Craig Sellars, as previously announced on 14 March 2024 and approved by shareholders on 27 June 2024. The Company issued 6,666,667 fully paid ordinary shares at 0.15 per share to Craig Sellars on 25 July 2024.
15 July 2024	The Company has received a binding purchase order for 5,000 additional 3Dicom patient annual licenses.
25 July 2024	 The Company has issued the following securities following the shareholders' approval on 27 June 2024: 336,364 fully paid ordinary shares to Director Andrew Just in lieu of cash payment of Director fees. 378,218 fully paid ordinary shares to Director Howard Digby in lieu of cash payment of Director fees. 1 million fully paid ordinary shares to Nigel Brown (subject to 24-month voluntary escrow) 2,775,000 fully paid ordinary shares to the Company's employees as a result of the conversion of vested performance rights, pursuant to the terms of the Company's Employee Incentive Plan. 8 million unlisted options exercisable at 0.15 and expiring 25 July 2027 to Shaw and Partners Limited (or their nominee/s). 10 million performance rights to Mr. Denning Chong, subject to vesting conditions.
	Refer to Notice of Meeting dated 21 May 2024 for further details in respect of the above allotments.
19 August 2024	The following Company securities lapsed and expired:
1)	 - 800,000 options with an exercise price of \$0.24 expired on 19 August 2024.
Ď.	 - 500,000 options with an exercise price of \$0.30 expiring 30 November 2025 lapsed as conditions have not been satisfied.
	- 625,000 performance rights lapsed of conditional right to securities as conditions have not been satisfied.

o other matter or circumstance has arisen since 30 June 2024 that has significantly affected, or may significantly affect the Group's perations, the results of those operations, or the Group's state of affairs in future financial years.

Singular Health Group Limited and its controlled entities Consolidated entity disclosure statement As at 30 June 2024



		Ownership					
		Place formed /	interest				
Entity name	Entity type	Country of incorporation	%	Tax residency			
Singular Health Group							
Limited	Body Corporate	Australia	100.00%	Australia			
Singular Health Pty Ltd	Body Corporate	Australia	100.00%	Australia			
Singular 3DP Pty Ltd	Body Corporate	Australia	100.00%	Australia			
Singular Health Pte Ltd	Body Corporate	Singapore	100.00%	Australia			
Singular International							
Medical Technology Ltd	Body Corporate	Macau, China	50.00%	China			

Singular Health Group Limited (the "head entity") and its wholly owned eligible subsidiaries intend to form a tax consolidated group from 1 July 2023.

Singular Health Group Limited and its controlled entities **Directors' declaration** 30 June 2024



In the Directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in note 1 to the financial statements;
- the attached financial statements and notes give a true and fair view of the Group's financial position as at 30 June 2024 and of its performance for the financial year ended on that date;
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable; and
- the information disclosed in the attached consolidated entity disclosure statement is true and correct.

The Directors have been given the declarations required by section 295A of the Corporations Act 2001.

Signed in accordance with a resolution of Directors made pursuant to section 295(5)(a) of the Corporations Act 2001. On behalf of the Directors

Penning Chong Managing Director 29 August 2024



nexia.com.au

Independent Auditor's Report to the Members of Singular Health Group Limited

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Singular Health Group Ltd (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 30 June 2024, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policy information, the consolidated entity disclosure statement and the directors' declaration.

In our opinion, the accompanying financial report of the Group is in accordance with the *Corporations Act* 2001 (the Act), including:

(i) giving a true and fair view of the Group's financial position as at 30 June 2024 and of its performance for the year then ended; and

(ii) complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor's Responsibility for the audit of the Financial Report section of our report. We are independent of the Group in accordance with the auditor independence requirements of the Act and the ethical requirements of the Accounting Professional & Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the Act, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Material Uncertainty Related to Going Concern

We draw attention to Note 1 (b) in the financial report, which indicates that the Group incurred an operating loss of \$4,924,704 during the year ended 30 June 2024 (30 June 2023: \$5,390,318) and a cash outflow from operating activities of \$2,440,289 for the year ended 30 June 2024 (30 June 2023: \$2,402,669). The Group will be required to generate further funding to meet its planned expenditure for a period of at least twelve months from the date of this report. This condition, along with other matters as set forth in Note 1 (b), indicate the existence of a material uncertainty that may cast significant doubt about the Group's ability to continue as a going concern and therefore the Group may be unable to realise its assets and discharge its liabilities in the normal course of business. Our opinion is not modified in respect of this matter.

Advisory. Tax. Audit.

ACN 145 447 105

Nexia Perth Audit Services Pty Ltd (ABN 27 145 447 105) is a firm of Chartered Accountants. It is affiliated with, but independent from Nexia Australia Pty Ltd. Nexia Australia Pty Ltd is a member of Nexia International, a leading, global network of independent accounting and consulting firms. For more information please see www.nexia.com. au/legal. Neither Nexia International nor Nexia Australia Pty Ltd provide services to clients.



Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter	How our audit addressed the key audit matter
Share-based payments	Our procedures included, amongst others:
 (Refer to Note 11 Share-based payments and Note 26 Reserves in the financial report) During the year ended 30 June 2024, a number of options and performance rights were issued. The Group recorded share-based payments expense of \$1,186,081 for continuing operations (note 11) and \$99,000 for discontinued operations (note 4). The value of share-based payments is a key audit matter due to it being a material transaction with members of key management personnel and the valuation of which involved significant judgment and accounting estimates. 	 Verifying the key terms of equity settled share-based payments in respect of the award of performance rights and options over common shares for rendering services by key management personnel and employees to the underlying shareholder approval and award documents; Testing the accuracy of the share-based payments amortisation over the vesting periods and recording of expense in the Statement of profit or loss and other comprehensive income and increase to the share-based payments reserve; Checking the completeness of share-based payments; and Checking the appropriateness of the disclosures of share-based payments arrangements in the financial report.
Assets and liabilities of disposal groups classified as held for sale (Refer to Note 17 Assets of disposal groups classified as held for sale in the financial report and Note 24 Liabilities directly associated with assets classified as held for sale) During the year ended 30 June 2024, a decision was made by the Directors to sell the Group's subsidiary company, Singular 3DP Pty Ltd (Singular 3DP). The assets and liabilities of disposal groups classified as held for sale is considered a key audit matter due to judgment applied in determining whether the assets and liabilities of disposal groups classified as held for sale are being carried at the lower of the carrying amount and fair value less costs to sell. Further, the separation of Singular 3DP into discontinued operations is important to understanding the	 Our procedures included, amongst others: Checking the appropriateness of management's assessment of the proposed sale of Singular 3DP meeting the requirements of AASB 5 <i>Non-current Assets Held for Sale and Discontinued Operations</i> (AASB 5); Assessing managements accounting treatment of the proposed sale of Singular 3DP which included critically assessing that the carrying value of assets and liabilities is at the lower of the carrying amount and fair value less costs to sell; and Checking the appropriateness of the disclosures in the financial report in accordance with AASB 5.



Other information

The directors are responsible for the other information. The other information comprises the information in the Group's annual report for the year ended 30 June 2024, but does not include the financial report and the auditor's report thereon.

Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of the other information we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the Financial Report

The directors of the Company are responsible for the preparation of:

- a) the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view in accordance with Australian Accounting Standards and the Act; and
- b) the consolidated entity disclosure statement that is true and correct in accordance with the Act, and

for such internal control as the directors determine is necessary to enable the preparation of:

- i) the financial (other than the consolidated entity disclosure statement) report that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
- ii) the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at The Australian Auditing and Assurance Standards Board website at:

<u>www.auasb.gov.au/admin/file/content102/c3/ar2_2020.pdf</u>. This description forms part of our auditor's report.



Report on the Remuneration Report

Opinion on the Remuneration Report

We have audited the Remuneration Report included in pages 16 to 24 of the Directors' Report for the year ended 30 June 2024.

In our opinion, the Remuneration Report of Singular Health Group Limited for the year ended 30 June 2024 complies with section 300A of the Act.

Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the Act. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

NPAS

Nexia Perth Audit Services Pty Ltd

a. 12

Justin Mulhair Director

Perth, Western Australia 29 August 2024

Singular Health Group Limited and its controlled entities **Corporate governance statement** 30 June 2024



Corporate Governance Statement

In fulfilling its obligations and responsibilities to its various stakeholders, the Board is a strong advocate of corporate governance. This statement outlines the principal corporate governance procedures of Singular Health Group Limited ("Company" or "Group"). The Board of Directors ("Board") supports a system of corporate governance to ensure that the management of Singular Health Group Limited is conducted to maximise shareholder wealth in a proper and ethical manner.

ASX Corporate Governance Council Recommendations

The Board has adopted corporate governance policies and practices consistent with the ASX Corporate Governance Council's Principles of Good Corporate Governance and Best Practice Recommendations ("ASX Principles and Recommendations 4th Edition") where considered appropriate for Group of Singular Health Group Limited size and nature. Such policies include, but are not limited to the Board Charter, Board Committee Charters, Code of Conduct, Trading in Securities, Continuous Disclosure, Shareholder Communication and Risk Management Policies.

Further details in respect to the Group's corporate governance practises and copies of Group's corporate governance policies and the 2024 Corporate Governance Statement, approved by the Board, are available of the Group's website:

Singular Health Group Limited and its controlled entities **ASX Additional Information** 30 June 2024



Additional information required by the ASX Limited Listing Rules not disclosed elsewhere in this Annual Report is set out below.

1. Shareholdings

The issued capital of the Company as at 26 August 2024 is 206,759,304 ordinary fully paid shares (inclusive of 1,000,000 ordinary shares escrowed until 25 July 2026), 36,200,000 performance rights, and 87,038,286 unlisted options (details below).

All issued ordinary fully paid shares carry one vote per share.

Ordinary Shares

Shares Range	Holders	Units	%
above 0 up to and including 1,000	180	118,419	0.06%
above 1,000 up to and including 5,000	669	1,882,690	0.91%
above 5,000 up to and including 10,000	312	2,541,637	1.23%
above 10,000 up to and including 100,000	587	21,927,523	10.61%
above 100,000	227	180,289,035	87.20%
Totals	1,975	206,759,304	100.00%

Onmarketable parcels

Top 20 Shareholders as at 26 August 2024

\neg	Name	Number of shares	%
1	MARIN AND SONS STRATEGIES LLC	13,636,363	6.60%
	MR SIM TEK TAN	9,003,091	4.35%
4 3	CHONG LING DIAMOND CHEONG	7,065,754	3.42%
\mathbf{O}^{4}	MR CRAIG SELLARS	6,666,667	3.22%
€	STATEWIDE NATIONAL SERVICES PTY LTD	6,000,000	2.90%
6	SKYLINE CORPORATION PTY LTD	5,068,539	2.45%
9	JLI ENTERPRISES PTY LTD <jli a="" c=""></jli>	4,900,000	2.37%
98	JCC HEALTH PTY LTD <the a="" c="" jde="" medvr=""></the>	4,640,869	2.24%
9	SYLVAN CAPITAL PTE LTD	3,500,000	1.69%
010	MS WEI ZHENG	3,326,224	1.61%
11	MR ANTHONY GALVIN KHANG CHUANG LIM	3,192,359	1.54%
12	JDE CAPITAL PTY LTD <jde a="" c="" capital=""></jde>	3,167,706	1.53%
13	MR QINGYUAN ZHANG	3,136,364	1.52%
14	MR PAK LIM KONG	3,132,292	1.51%
15	GARRY TET KHENG CHONG	3,000,000	1.45%
16	MR KOSTADIN JIVKOV MANOLEV	2,828,821	1.37%
17	MR ILIA MANOLEV	2,713,878	1.31%
18	PENINSULA TREESCAPE PTY LTD <the a="" c="" cardinals=""></the>	2,700,000	1.31%
19	RAFFE CAPITAL PTY LTD	2,272,727	1.10%
20	BNP PARIBAS NOMINEES PTY LTD <ib au="" noms="" retailclient=""></ib>	2,154,683	1.04%
	Total Top 20	92,106,337	44.55%
	Total remaining holders balance	114,652,967	55.5%
	Total issued capital	206,759,304	100.00%

Singular Health Group Limited and its controlled entities **ASX Additional Information** 30 June 2024



3. Substantial Shareholders

Name of Substantial Shareholder	Number of shares held	Shareholding %	
Marin and Sons Strategies LLC	13,636,363	6.98%	

Restricted Securities Subject to escrow period 4.

Security class	Number of securities held
SHGESC24 - VOLUNTARY ESCROWED SHARES TO 25/07/2026	1,000,000

5. Unquoted securities

There are 36,200,000 performance rights and 87,038,286 unlisted options over shares in the Company as at 26 August 2024 as follows:

Security Code	Security Name	Number of holders	Number of options on issue	Number of Performance Rights on issue
SHGOPT01	UNLISTED OPTIONS @ \$0.30	7	19,250,000	-
SHGOPT02	UNLISTED OPTIONS @ \$0.30 EXP 20/12/25	12	2,030,000	-
SHGOPT07	UNL OPTIONS @ \$0.40 EXP 23/12/2025	4	5,000,000	-
SHGOPT08	UNL OPTIONS @ \$0.20 EXP 25/01/2026	1	1,720,000	-
SHGOPT09	UNL OPTIONS @ \$0.10 EXP 26/06/2026	52	19,674,651	-
SHGOPT10	UNLISTED OPTIONS @ \$0.10 EXP 14/08/26	3	3,636,363	-
SHGOPT11	UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027	7	19,500,000	-
SHGOPT12	UNLISTED OPTIONS @ \$0.10 EXP 09/02/2027	2	7,727,272	-
SHGOPT13	UNLISTED OPTIONS @ \$0.15 EXP 25/07/2027	12	8,500,000	-
SHGPERFB12	PERFORMANCE RIGHTS - CLASS B	1	-	150,000
SHGPERFB24	PERFORMANCE RIGHTS - CLASS B	6	-	4,850,000
SHGPRA	PERFORMANCE RIGHTS - TRANCHE A	6	-	4,500,000
SHGPRB	PERFORMANCE RIGHTS - TRANCHE B	6	-	2,250,000
SHGPRC	PERFORMANCE RIGHTS EXP 8/12/2027	8	-	9,950,000
SHGPRD	CONSULTANCY PERF RIGHTS EXP 20/09/25	1	-	4,500,000
SHGPRE	PERFORMANCE RIGHTS EXP 30/06/2028	2	-	10,000,000
<u> </u>			87,038,286	36,200,000

Singular Health Group Limited and its controlled entities ASX Additional Information 30 June 2024



6. Holders of Unlisted Securities over 20%

	HOLDER OVER 20%	SHGOPT10 \$0.10 EXP 14/08/26	SHGOPT08 \$0.20 EXP 25/01/2026	SHGPRB	SHGPERFB	SHGPRA	SHGPRD	SHGOPT12	SHGOPT07 \$0.40 EXP 3/12/2025	SHGOPT13	SHGOPT02 @ \$0.30 EXP 20/12/25	SHGOPT01 @ \$0.30
	BRIGHTSTAR CAPITAL PTY LTD	1,818,181										
	QINGYUAN ZHANG	909,091										
	WEI ZHENG	909,091										
	MARIN AND SONS INC						4,500,000					
	MARIN AND SONS STRATEGIES LLC							6,818,181				
	SHAW AND PARTNERS LIMITED									3,500,000		
	GLOBAL3D PTY LTD	-	1,720,000									
	JCC HEALTH PTY LTD				1,200,000							4,500,000
U U	JDE CAPITAL PTY LTD	-	-	500,000		1,000,000						
	J J TAN (PERTH) PTY LTD				1,200,000							
Ω	THOMAS			500,000		1,000,000					500,000	
	REENERGISE AUSTRALIA PTY LTD			500,000		1,000,000						
U	THOMAS			500,000	1,500,000	1,000,000						6,000,000
	PHILLIP CAWOOD								1,950,000			
	PAC PARTNERS								2,000,000			
L	ROCKLEY CAPITAL								1,050,000			
Ľ	TOTAL Holdings over 20%	3,636,363	1,720,000	2,000,000	3,900,000	4,000,000	4,500,000	6,818,181	5,000,000		500,000	10,500,000

7. On-market buyback

L

There is currently no on-market buyback program for any of Singular Health Group Limited's listed securities.

8. Group cash and assets

In accordance with Listing Rule 4.10.19, the Group confirms that it has been using the cash and assets it had acquired at the time of admission and for the year ended 30 June 2024 in a way that is consistent with its business objective and strategy.